Substituted aminoquinolones as immunoactivated DGK [alpha] inhibitors

Abstract

The present invention encompasses aminoquinolone compounds of general formula (I): # imgabs0 # wherein R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein; processes for preparing the compounds; intermediate compounds useful in the preparation of such compounds; pharmaceutical compositions and conjugates comprising such compounds; and to the use of said compounds as a sole agent or in combination with other active ingredients for the preparation of a pharmaceutical composition for the treatment and / or prophylaxis of diseases, in particular diacylglycerol kinase alpha modulated conditions.

Description

[0001] This application is a divisional application of the Chinese invention patent application with application number 202080094610.6 filed on November 24, 2020, and invention name “Substituted aminoquinolones as DGKα inhibitors of immune activation”.

[0002] The present invention encompasses substituted aminoquinolone compounds of general formula (I) as described and defined herein, processes for preparing said compounds, intermediate compounds useful in preparing said compounds, pharmaceutical compositions and conjugates comprising said compounds, and the use of said compounds as single agents or in combination with other active ingredients for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, in particular conditions regulated by diacylglycerol kinase alpha (DGKalpha, DGKα).

[0003] Compounds of general formula (I) inhibit DGKα and enhance T cell-mediated immune responses. This represents a novel strategy for using a patient's own immune system to overcome numerous neoplastic diseases (particularly cancer) and thereby enhance anti-tumor immunity. Furthermore, the compounds are particularly useful for treating conditions such as viral infections or conditions associated with dysregulated immune responses or other conditions associated with aberrant DGKα signaling.

[0004] The present invention also relates to uses, and respectively relates to uses of the compound of general formula (I) in preparing a pharmaceutical composition for enhancing T cell-mediated immune response.

[0005] The present invention also relates to uses, and specifically to uses of the compound of general formula (I) in preparing a pharmaceutical composition for treating cancer.

[0006] The present invention also relates to uses, respectively uses of the compounds of general formula (I) for preparing pharmaceutical compositions for treating or preventing fibrotic disorders, viral infections, heart diseases and lymphoproliferative diseases. Background Art

[0007] Diacylglycerol kinases (DGKs) represent a family of enzymes that catalyze the phosphorylation of the membrane lipid sn-1,2 diacylglycerol (DAG) to form phosphatidic acid (PA) (Eichmann and Lass, Cell Mol Life Sci. 2015; 72: 3931). In T cells, DAG is formed downstream of the T cell receptor (TCR) after activation of the γ1 isoform of phospholipase C (PLCγ1) and cleavage of phosphatidylinositol-4,5-bisphosphate (PIP2) into DAG and another second messenger, inositol-1,4,5-triphosphate (IP3) (Krishna and Zhong, Front. Immunol 2013, 4, 178). However, IP3 is important in promoting calcium release from the endoplasmic reticulum, and DAG interacts with other proteins important in TCR signal transduction, such as protein kinase Cθ (Quann et al., Nat Immunol 2011(7), 647) and Ras activation protein RasGRP1 (Krishna and Zhong, Front. Immunol 2013, 4: 178). Although three isoforms of DGK are known to exist in T cells [DGKα (DGKalpha), DGKδ (DGKdelta) and DGKζ (DGKzeta)], only DGKα and DGKζ are thought to play an important role in promoting DAG metabolism downstream of TCR (Joshi and Koretzky, Int. J. Mol. Sci. 2013, 14, 6649).

[0008] Targeting the activity of DGKα in T cells by germline deletion or with chemical inhibitors results in enhanced and sustained downstream signaling in T cells, as assessed by prolonged phosphorylation of downstream molecules such as extracellular signal-related kinase 1 / 2 (ERK1 / 2) (Zhong et al., Nat Immunol 2003, 4, 882; Olenchock et al., Nat Immunol 2006, 7, 1174; Riese et al., J. Biol. Chem 2011, 286, 5254). In addition, overexpression of DGKα induces a state of reduced functional activity similar to an anergy-like state (Zha et al., Nat Immunol 2006, 7, 1166). Conversely, deletion of DGKα in T cells enhances the production of effector cytokines such as IL2 and IFNγ and increases proliferation (Zhong et al., Nat Immunol 2003, 4, 882; Olenchock et al., Nat Immunol 2006, 7, 1174).

[0009] These findings suggest that DGKα can be used as a useful target for enhancing the anti-tumor activity of T cells. The role of DGKα in anti-tumor response has recently been studied in human tumor-infiltrating CD8+ T cells (CD8-TIL) from patients with renal cell carcinoma (RCC) (Prinz et al., J. Immunol 2012, 188, 5990). CD8-TIL from RCC is defective in soluble granule exocytosis and their ability to kill target cells. Although the proximal signaling event response TCR engagement reaction is complete, CD8-TIL shows a decrease in ERK phosphorylation compared to non-tumor infiltrating CD8+ T cells. CD8-TIL rescues the killing ability of target cells with DGKα activity inhibitors, increases the basal level of ERK phosphorylation, and increases ERK phosphorylation stimulated by PMA / ionomycin.

[0010] Furthermore, Arranz-Nicolas et al. showed that DGK inhibitors not only promote Ras / ERK signaling, but also promote AP-1 (activator protein-1) transcription, promote DGKα membrane localization, reduce the need for costimulation, and cooperate with the enhanced activation after DGKζ silencing / deletion. In contrast to the enhanced activation triggered by pharmacological inhibition, DGKα silencing / genetic deletion leads to impaired Lck (lymphocyte-specific protein tyrosine kinase) activation and limited costimulatory responses. (Arranz-Nicolas et al., Canc Immun, Immunother 2018, 67(6), 965).

[0011] In addition, from DGKα - / - and DGKζ - / - Mouse antigen-specific CD8 + T cells show enhanced expansion and increased cytokine production after (lymphocytic choriomeningitis virus) infection (Shin et al. J. Immunol, 2012).

[0012] In addition, adoptive transfer of CAR (chimeric antigen receptor)-T cells deleted in DGKα demonstrated that T cells were more effective in treating mouse mesothelioma (Riese et al., Cancer Res 2013, 73(12), 3566) and glioblastoma xenograft mouse models (Jung et al. Cancer Res. 2018, 78(16), 4692) compared to wild-type CAR T cells.

[0013] In addition to T cell regulation, DGKα also plays a role in cancer, mediating many aspects of cancer cell progression, including survival (Bacchiocchi et al., Blood, 2005, 106(6), 2175; Yanagisawa et al. Biochim Biophys Acta 2007, 1771, 462), migration and invasion of cancer cells (Baldanzi et al., Oncogene 2008, 27, 942; Fileigheddu et al., Anticancer Res 2007, 27, 1489; Rainero et al., J Cell Biol 2012, 196(2): 277). In particular, DGKα has been reported to be overexpressed in hepatocellular carcinoma (Takeishi et al., J Hepatol 2012, 57, 77) and melanoma cells (Yanagisawa et al., Biochim Biophys Acta 2007, 1771, 462), while other reports have shown that the growth of colon and breast cancer cell lines is significantly inhibited by DGKα-siRNA16, and that the DGKα / atypical PKC / b1 integrin signaling pathway is essential for the matrix invasion of breast cancer cells (Rainero et al., PLoS One 2014, 9(6): e97144). In addition, expression in lymph node metastases is also higher than that in primary breast tumors (Hao et al., Cancer 2004, 100, 1110).

[0014] Furthermore, studies testing the importance of DGKα in glioblastoma multiforme (GBM) cells found that co-administration of the relatively nonspecific DGKα inhibitor R59022 resulted in reduced growth of GBM tumors injected intracranially (Dominguez et al. Cancer Discov 2013, 3(7):782).

[0015] Furthermore, DGKα promotes the progression of esophageal squamous cell carcinoma (ESCC), supporting DGKα as a potential target for ESCC treatment (Chen et al., Oncogene, 2019, 38(14)2533).

[0016] Furthermore, pharmacological inhibition of DGK reduced airway inflammation and airway hyperresponsiveness in mice and also inhibited T helper 2 (T H 2) Differentiation reduces bronchoconstriction in human airway samples in vitro (Singh et al., Sci Signal. 2019, 12, eaax3332).

[0017] Furthermore, inhibition of DGKα has the potential to reverse the life-threatening Epstein-Barr virus (EBV)-associated immunopathology that occurs in patients with X-linked lymphoproliferative disorder (XLP-1) (Ruffo et al., Sci Transl Med. 2016, 13, 8, 321; Velnati et al., Eur J Med Chem. 2019, 164, 378).

[0018] Furthermore, DGKα exacerbates cardiac injury after ischemia / reperfusion heart disease (Sasaki et al., Heart Vessels, 2014, 29, 110).

[0019] Together, the results of these studies suggest that inhibition of DGKα activity in T cells and tumor cells may prove valuable in generating stronger immune responses against pathogens and tumors and in ameliorating Th2-driven (ato) immune diseases (in rebalancing the immune system). Furthermore, inhibition of DGKα activity has therapeutic potential in directly targeting tumors and addressing fibrotic conditions, viral infection-related pathologies, heart disease, and lymphoproliferative diseases.

[0020] Existing technology

[0021] DGKα inhibitors have been reported in the literature. R59022 (A) was identified as acting on DGKα in erythrocytes (deChaffoy de Courcelles et al., J. Biol. Chem. Vol. 260, No. 29, (1985), p15762-70). The structurally related R59949 (B) was identified as acting on DGKα in T-lymphocytes by inhibiting the conversion of 1,2-diacylglycerol to their respective phosphatidic acids (Jones et al., J. Biol. Chem. Vol. 274, No. 24, (1999), p16846-52). Ritanserin (C), originally identified as a serotonin receptor antagonist, showed equivalent activity against DGKα as the two R compounds (A) and (B) (Boroda et al., BioChem. Pharm. 123, (2017), 29-39).

[0022]

[0023] Further structure, CU-3(D) was identified as the first compound with submicromolar inhibitory activity against DGKα (Sakane et al., J. Lipid Res. Vol 57, (2016), p368-79).

[0024]

[0025] AMB639752(E) is described as another DGKα selective inhibitor with micromolar activity (S. Velnati et al. Eur J. Med. Chem 2019, 164, p378-390.).

[0026]

[0027] WO2020 / 151636 relates to azaquinolinones as PDE9 inhibitor compounds for the treatment of PDE9-mediated diseases.

[0028] WO2020 / 143626 relates to quinolinones as PDE9 inhibitor compounds for the treatment of PDE9-mediated diseases.

[0029] WO2020 / 182076 relates to the use of phosphodiesterase inhibitor compounds in the preparation of medicaments for treating heart failure in mammals.

[0030] WO2020 / 006016 and WO2020 / 006018 describe naphthydrinone compounds as T cell activators that inhibit the activity of DGKα and / or DGKζ for the treatment of viral infections and proliferative disorders, such as cancer.

[0031] WO2017 / 019723A1 relates to azacyanoquinolinone compounds that can be used as therapeutic agents to treat central nervous system disorders associated with phosphodiesterase 9 (PDE9). It also relates to the use of the compounds for treating neurological and psychiatric disorders.

[0032] WO 2004 / 074218 describes MIF inhibitors and their various uses, including for the treatment of cancer.

[0033] WO 2007 / 109251 describes the use of TNFα inhibitors for the treatment of diseases, including the treatment of cancer.

[0034] WO 2012 / 142498 and WO 2012 / 009649 describe MIF inhibitors and their various uses, including cancer treatment. These patent applications claim protection for a very large number of compounds. However, many of these theoretical compounds are not specifically disclosed.

[0035] However, the prior art does not describe:

[0036] The specific substituted aminoquinolone compounds of the general formula (I) of the present invention described and defined herein

[0037] Compounds, i.e., compounds having a 2-oxo-1,2-dihydroquinoline core, which:

[0038] · A methyl or ethyl group at its 1-position,

[0039] · has a cyano group, a carbamoyl group, an alkylcarbamoyl group, a dialkylcarbamoyl group or an alkoxycarbonyl group at its 3-position,

[0040] carries a pyrrolidinyl-, piperidinyl- or azepanyl group at its 4-position; and

[0041] carries a phenyl-, naphthyl- or 5- to 10-membered heteroaryl group as a substituent of the pyrrolidinyl-, piperidinyl- or azepanyl group,

[0042] or a stereoisomer, tautomer, N-oxide, hydrate, solvate, salt thereof, or a mixture thereof, as described and defined herein, and hereinafter referred to as "a compound of formula (I)" or "a compound of the present invention",

[0043] or with their pharmacological activity.

[0044] It would be desirable to provide new compounds having prophylactic and therapeutic properties.

[0045] Therefore, the object of the present invention is to provide compounds for the prophylactic and therapeutic use of DGKα-mediated disorders in a T cell immunostimulatory or immunomodifying manner and pharmaceutical compositions comprising these compounds.

[0046] Conditions modulated by DGKα include those with dysregulated immune responses, particularly in the immunosuppressive tumor microenvironment of cancer, autoimmune diseases, viral infections, and other conditions associated with aberrant DGKα signaling (e.g., fibrotic diseases). The compounds can be used as single agents or in combination with other active ingredients.

[0047] It has now been found, and this forms the basis of the present invention, that the compounds of the present invention have unexpected and advantageous properties.

[0048] In particular, it has been unexpectedly found that the compounds of the present invention effectively inhibit DGKα protein and enhance T cell-mediated immunity. Therefore, they provide new structures for treating human and animal diseases, especially cancer, and are therefore useful for treating or preventing hyperproliferative diseases such as cancer. Summary of the Invention

[0049] According to a first aspect, the present invention covers compounds of general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof:

[0050]

[0051] in:

[0052] R 1 represents a group selected from the group consisting of: cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 ,

[0053] R 2 represents a group selected from the group consisting of phenyl, naphthyl and 5- to 10-membered heteroaryl,

[0054] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[0055] and

[0056] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0057] C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0058] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[0059] -(CH2)3-, -CH2-CH(OH)-CH2-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-CH(CH3)-O-, -CH2-O-CH2-, -O- (CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O-, -OC(CH3)2-O-, -O-(CH2)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-(C(CH2)3)-、-N(R 18 )-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O)-N(R 18 )-,

[0060] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0061] and

[0062] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0063] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0064] and

[0065] wherein the C1-C6-alkyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0066] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0067] and

[0068] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0069] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0070] and

[0071] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0072] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0073] and

[0074] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0075] and

[0076] wherein the C3-C6-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0077] and

[0078] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0079] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0080] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0081] C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0082] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0083] and

[0084] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0085] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0086] and

[0087] wherein the C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[0088] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0089] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0090] and

[0091] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0092] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0093] and

[0094] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0095] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0096] and

[0097] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0098] and

[0099] wherein the C2-C6-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[0100] and

[0101] wherein the C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl and C1-C4-haloalkyl,

[0102] and

[0103] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0104] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0105] R 4 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0106] C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2-alkoxy)-(C1-C6-alkoxy)-, C1-C4-haloalkoxy, -O-(C1-C4-alkyl)-C(=O)OR 15 、-O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C6-cycloalkyloxy, -S(=O)R 14 、-S(=O)2R 14 , cyano, nitro, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-N(R 16 )(R 20 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0107] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0108] and

[0109] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0110] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R9 )(R 10 ) and oxo,

[0111] and

[0112] wherein the C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0113] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0114] and

[0115] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0116] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0117] and

[0118] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0119] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0120] and

[0121] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0122] and

[0123] wherein the C1-C6-alkoxy group is optionally substituted by an oxiran-2-yl group,

[0124] and

[0125] wherein the C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0126] and

[0127] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0128] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0129] R 5 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0130] C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C2-C6-alkoxy)-, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0131] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0132] and

[0133] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0134] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0135] and

[0136] wherein the C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[0137] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0138] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0139] and

[0140] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0141] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0142] and

[0143] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0144] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0145] and

[0146] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0147] and

[0148] wherein the C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0149] and

[0150] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0151] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0152] R 6 represents a hydrogen atom or a fluorine atom, or a group selected from the following:

[0153] C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, hydroxy and oxo,

[0154] R 7 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0155] C1-C4-alkyl, C1-C4-alkoxy, hydroxy and cyano,

[0156] R 8 represents a group selected from methyl and ethyl,

[0157] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a group selected from:

[0158] C1-C4-alkyl, C2-C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkoxy)-(C2-C4-alkyl)-, C3-C4-cycloalkyl and C2-C4-haloalkyl,

[0159] or

[0160] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[0161] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl is optionally substituted one, two or three times, and each substituent is independently selected from a halogen atom or a group selected from the following:

[0162] C1-C4-alkyl, C3-C4-cycloalkyl, hydroxy and oxo,

[0163] or

[0164] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[0165] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0166] C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, hydroxy and oxo,

[0167] R 11 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, phenyl and 5- or 6-membered heteroaryl,

[0168] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0169] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0170] R 12 represents a hydrogen atom or a C1-C4-alkyl group,

[0171] R 13 represents a hydrogen atom or a radical selected from C1-C6-alkyl, phenyl and 5- or 6-membered heteroaryl,

[0172] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0173] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0174] R 14 represents a radical selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, phenyl and 5- or 6-membered heteroaryl,

[0175] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0176] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0177] R 15represents a hydrogen atom or a C1-C4-alkyl group,

[0178] R 16 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C3-C4-cycloalkyl and C2-C4-haloalkyl,

[0179] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[0180] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0181] C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxy and oxo,

[0182] and

[0183] wherein the 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[0184] R 18 represents a hydrogen atom or a group selected from methyl and ethyl,

[0185] R 19 represents a hydrogen atom or a group selected from methyl and ethyl,

[0186] R 20 represents a (4- to 7-membered heterocycloalkyl)-(C1-C4-alkyl)- group,

[0187] wherein the (4- to 7-membered heterocycloalkyl) portion of the group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0188] C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxy and oxo,

[0189] m represents an integer selected from 1, 2 and 3,

[0190] and

[0191] n represents an integer selected from 1, 2 and 3.

[0192] According to a variant of the first aspect, the present invention covers compounds of the above general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[0193] R 1represents a group selected from the group consisting of: cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 ,

[0194] R 2 represents a group selected from the group consisting of phenyl, naphthyl and 5- to 10-membered heteroaryl,

[0195] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[0196] and

[0197] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0198] C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0199] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[0200] -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O-, and -OC(CH2)2-O-,

[0201] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0202] and

[0203] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0204] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0205] and

[0206] wherein the C1-C6-alkyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0207] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0208] and

[0209] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0210] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0211] and

[0212] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0213] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R9 )(R 10 ),

[0214] and

[0215] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0216] and

[0217] wherein the C3-C6-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0218] and

[0219] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0220] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0221] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0222] C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14)2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0223] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0224] and

[0225] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0226] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0227] and

[0228] wherein the C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[0229] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0230] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0231] and

[0232] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0233] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0234] and

[0235] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0236] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0237] and

[0238] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0239] and

[0240] wherein the C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0241] and

[0242] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0243] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0244] R 4 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0245] C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2-alkoxy)-(C1-C6-alkoxy)-, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, -S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14)2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0246] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0247] and

[0248] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0249] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0250] and

[0251] wherein the C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0252] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0253] and

[0254] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0255] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0256] and

[0257] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0258] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0259] and

[0260] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0261] and

[0262] wherein the C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0263] and

[0264] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0265] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0266] R 5 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0267] C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C2-C6-alkoxy)-, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0268] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0269] and

[0270] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0271] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0272] and

[0273] wherein the C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[0274] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0275] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0276] and

[0277] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0278] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0279] and

[0280] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0281] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0282] and

[0283] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0284] and

[0285] wherein the C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0286] and

[0287] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0288] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0289] R 6 represents a hydrogen atom or a fluorine atom, or a group selected from the following:

[0290] C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, hydroxy and oxo,

[0291] R 7 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0292] C1-C4-alkyl, C1-C4-alkoxy, hydroxy and cyano,

[0293] R 8 represents a group selected from methyl and ethyl,

[0294] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a group selected from:

[0295] C1-C4-alkyl, (C1-C4-alkoxy)-(C2-C4-alkyl)-, C3-C4-cycloalkyl and C2-C4-haloalkyl,

[0296] or

[0297] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[0298] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl is optionally substituted one, two or three times, and each substituent is independently selected from a halogen atom or a group selected from the following:

[0299] C1-C4-alkyl, C3-C4-cycloalkyl, hydroxy and oxo,

[0300] or

[0301] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[0302] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0303] C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, hydroxy and oxo,

[0304] R 11 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, phenyl and 5- or 6-membered heteroaryl,

[0305] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0306] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0307] R 12 represents a hydrogen atom or a C1-C4-alkyl group,

[0308] R 13 represents a hydrogen atom or a radical selected from C1-C6-alkyl, phenyl and 5- or 6-membered heteroaryl,

[0309] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0310] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0311] R 14 represents a radical selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, phenyl and 5- or 6-membered heteroaryl,

[0312] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0313] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0314] R 15 represents a hydrogen atom or a C1-C4-alkyl group,

[0315] R 16 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C3-C4-cycloalkyl and C2-C4-haloalkyl,

[0316] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[0317] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0318] C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxy and oxo,

[0319] and

[0320] wherein the 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[0321] and

[0322] n represents an integer selected from 1, 2 and 3.

[0323] definition

[0324] The term "substituted" means that one or more hydrogen atoms on the designated atom or group are replaced with a selected group from the designated group, provided that the normal valence of the designated atom in the existing situation is not exceeded. Combinations of substituents and / or variables are permissible.

[0325] The term "optionally substituted" means that the number of substituents may be equal to or different from zero. Unless otherwise indicated, an optionally substituted group may be substituted with as many optional substituents as can be accommodated by replacing hydrogen atoms with non-hydrogen substituents on any available carbon or nitrogen atom. Typically, the number of optional substituents (when present) may be 1, 2, 3 or 4, particularly 1, 2 or 3.

[0326] When a group in the compounds of the present invention is substituted, unless otherwise indicated, the group may be monosubstituted or polysubstituted by a substituent. Within the scope of the present invention, the meanings of all repeated groups are independent of one another. A group in the compounds of the present invention may be substituted by one, two or three identical or different substituents, in particular by one substituent.

[0327] As used herein, an oxo substituent represents an oxygen atom bonded to a carbon atom or a sulfur atom via a double bond.

[0328] If a composite substituent consists of more than one part, for example (C1-C2-alkoxy)(C1-C6-alkyl)-, a given part may be attached at any suitable position of the composite substituent, for example a C1-C2-alkoxy part may be attached to any suitable carbon atom of the C1-C6-alkyl part of the (C1-C2-alkoxy)(C1-C6-alkyl)- group. A hyphen at the beginning or end of such a composite substituent indicates the point of attachment of the composite substituent to the rest of the molecule. If a ring comprising carbon atoms and optionally one or more heteroatoms (for example nitrogen, oxygen or sulfur atoms) is substituted by a substituent, the substituent may be attached at any suitable position of the ring, being attached to a suitable carbon atom and / or a suitable heteroatom.

[0329] When used in the specification, the term "comprising" includes "consisting of".

[0330] If any item is referred to herein as "as referred to herein," it is meant to be referred to anywhere herein.

[0331] The terms used in this document have the following meanings:

[0332] The term "halogen atom" refers to a fluorine, chlorine, bromine or iodine atom, in particular a fluorine, chlorine or bromine atom.

[0333] The term "C1-C6-alkyl" refers to a straight-chain or branched saturated monovalent hydrocarbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2,3-dimethylbutyl, 1,2-dimethylbutyl or 1,3-dimethylbutyl, or an isomer thereof. In particular, the radical has 1, 2, 3, 4 or 5 carbon atoms (“C1-C5-alkyl”), for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl. More particularly, the radical has 1, 2, 3 or 4 carbon atoms (“C1-C4-alkyl”), for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl or tert-butyl, more particularly 1, 2 or 3 carbon atoms (“C1-C3-alkyl”), for example methyl, ethyl, n-propyl or isopropyl, more particularly 1 or 2 carbon atoms (“C1-C2-alkyl”), for example methyl or ethyl.

[0334] The term "C2-C4-alkyl" refers to a straight-chain or branched saturated monovalent hydrocarbon radical having 2, 3 or 4 carbon atoms, for example ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl or tert-butyl.

[0335] The term "C1-C6-hydroxyalkyl" refers to a linear or branched saturated monovalent hydrocarbon radical, wherein the term "C1-C6 alkyl" is as defined above, and wherein 1 or 2 hydrogen atoms are replaced by hydroxy groups, for example, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropyl-2-yl, 2-hydroxypropyl-2-yl, 2,3-dihydroxypropyl, 1,3-dihydroxypropyl-2-yl, 3-Hydroxy-2-methyl-propyl, 2-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl, 1-hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 1-hydroxypentyl, 2-hydroxypentyl, 3-hydroxypentyl, 4-hydroxypentyl, 5-hydroxypentyl, 1-hydroxyhexyl, 2-hydroxyhexyl, 3-hydroxyhexyl, 4-hydroxyhexyl, 5-hydroxyhexyl, 6-hydroxyhexyl or an isomer thereof. In particular, the radicals have 1, 2, 3 or 4 carbon atoms (“C1-C4-hydroxyalkyl”), for example hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropyl-2-yl, 2-hydroxypropyl-2-yl, 2,3-dihydroxypropyl, 1,3-dihydroxypropyl-2-yl, 3-hydroxy-2-methyl-propyl, 2-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl, 1-hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, or isomers thereof.

[0336] The term "C2-C4-hydroxyalkyl" refers to a straight-chain or branched saturated monovalent hydrocarbon radical having 2, 3 or 4 carbon atoms, wherein the term "C2-C4-alkyl" is as defined above and wherein 1 or 2 hydrogen atoms are replaced by hydroxy, for example 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxyprop-2-yl, 2-hydroxyprop-2-yl, 2,3-dihydroxypropyl, 1,3-dihydroxyprop-2-yl, 3-hydroxy-2-methyl-propyl, 2-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl, 1-hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl or 4-hydroxybutyl, or an isomer thereof.

[0337] The term "C1-C6-haloalkyl" refers to a straight or branched saturated monovalent hydrocarbon radical, wherein the term "C1-C6-alkyl" is as defined above, and wherein one or more hydrogen atoms are replaced identically or differently by a halogen atom. In particular, the halogen atom is a fluorine atom. The C1-C6-haloalkyl is, for example, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl, 1,3-difluoroprop-2-yl, 4,4,4-trifluorobutyl, 5,5,5-trifluoropentyl or 6,6,6-trifluorohexyl. In particular, the radical has 1, 2, 3 or 4 carbon atoms ("C1-C4-haloalkyl"), for example fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl, 1,3-difluoroprop-2-yl or 4,4,4-trifluorobutyl.

[0338] The term "C1-C6-alkoxy" refers to a linear or branched saturated monovalent radical of the formula (C1-C6-alkyl)-O-, wherein the term "C1-C6-alkyl" is as defined above, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, pentoxy, isopentoxy or n-hexoxy, or an isomer thereof. In particular, such radicals have 1, 2, 3 or 4 carbon atoms ("C1-C4-alkoxy"), for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy or tert-butoxy.

[0339] The term "C1-C6-haloalkoxy" refers to a linear or branched, saturated, monovalent C1-C6-alkoxy group, as defined above, in which one or more hydrogen atoms are replaced by halogen atoms, identically or differently. In particular, the halogen atoms are fluorine atoms. The C1-C6-haloalkoxy group is, for example, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy or pentafluoroethoxy.

[0340] The term "C2-C6-alkenyl" refers to a straight or branched monovalent hydrocarbon radical containing one or two double bonds and having 2, 3, 4, 5 or 6 carbon atoms, it being understood that where the alkenyl group contains two double bonds, the double bonds may be conjugated to each other or to form an allene. The alkenyl group is, for example, vinyl (or "vinyl"), prop-2-en-1-yl (or "allyl"), prop-1-en-1-yl, but-3-enyl, but-2-enyl, but-1-enyl, pent-4-enyl, pent-3-enyl, pent-2-enyl, pent-1-enyl, hex-5-enyl, hex-4-enyl, hex-3-enyl, hex-2-enyl, hex-1-enyl, prop-1-en-2-yl (or "isopropenyl"), 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2-methylprop-1-enyl, 1- Methylprop-1-enyl, 3-methylbut-3-enyl, 2-methylbut-3-enyl, 1-methylbut-3-enyl, 3-methylbut-2-enyl, 2-methylbut-2-enyl, 1-methylbut-2-enyl, 3-methylbut-1-enyl, 2-methylbut-1-enyl, 1-methylbut-1-enyl, 1,1-dimethylprop-2-enyl, 1-ethylprop-1-enyl, 1-propylvinyl, 1-isopropylvinyl, 4-methylpent-4-enyl, 3-methylpent-4-enyl, 2-methylpent-4-enyl, 1-methylpent-4-enyl , 4-methylpent-3-enyl, 3-methylpent-3-enyl, 2-methylpent-3-enyl, 1-methylpent-3-enyl, 4-methylpent-2-enyl, 3-methylpent-2-enyl, 2-methylpent-2-enyl, 1-methylpent-2-enyl, 4-methylpent-1-enyl, 3-methylpent-1-enyl, 2-methylpent-1-enyl, 1-methylpent-1-enyl, 3-ethylbut-3-enyl, 2-ethylbut-3-enyl, 1-ethylbut-3-enyl, 3-ethylbut-2-enyl, 2-ethylbut-2-enyl, 1-ethyl but-2-enyl, 3-ethylbut-1-enyl, 2-ethylbut-1-enyl, 1-ethylbut-1-enyl, 2-propylprop-2-enyl, 1-propylprop-2-enyl, 2-isopropylprop-2-enyl, 1-isopropylprop-2-enyl, 2-propylprop-1-enyl, 1-propylprop-1-enyl, 2-isopropylprop-1-enyl, 1-isopropylprop-1-enyl, 3,3-dimethylprop-1-enyl, 1-(1,1-dimethylethyl)vinyl, buta-1,3-dienyl, penta-1,4-dienyl or hexa-1,5-dienyl.

[0341] The term "C2-C6-alkynyl" refers to a monovalent straight-chain or branched hydrocarbon radical containing one triple bond and having 2, 3, 4, 5 or 6 carbon atoms, in particular 2, 3 or 4 carbon atoms ("C2-C4-alkynyl"). The C2-C6-ynyl group is, for example, ethynyl, prop-1-ynyl, prop-2-ynyl (or "propargyl"), but-1-ynyl, but-2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1-methylprop-2-ynyl, 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 1-methylbut-2-ynyl, 3-methylbut-1-ynyl, 1-ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1-methylpent-4-ynyl, 2-methylpent-3-ynyl, 1-methylpent-3-ynyl, 4-methylpent-2-ynyl, 1-methylpent-2-ynyl, 4-methylpent-1-ynyl, 3-methylpent-1-ynyl, 2-ethylbut-3-ynyl, 1-ethylbut-3-ynyl, 1-ethylbut-2-ynyl, 1-propylprop-2-ynyl, 1-isopropylprop-2-ynyl, 2,2-dimethylbut-3-ynyl, 1,1-dimethylbut-3-ynyl, 1,1-dimethylbut-2-ynyl or 3,3-dimethylbut-1-ynyl.

[0342] The term "C3-C6-cycloalkyl" refers to a saturated monovalent monocyclic hydrocarbon ring containing 3, 4, 5 or 6 carbon atoms. The C3-C6-cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In particular, the group has 3, 4 or 5 carbon atoms ("C3-C5-cycloalkyl"), for example cyclopropyl, cyclobutyl or cyclopentyl. In particular, the group has 3 or 4 carbon atoms ("C3-C4-cycloalkyl"), for example cyclopropyl or cyclobutyl.

[0343] The term "C4-C6-cycloalkenyl" refers to a monocyclic hydrocarbon ring containing 4, 5 or 6 carbon atoms and a double bond. In particular, the ring contains 5 or 6 carbon atoms ("C5-C6-cycloalkenyl"). The C4-C6-cycloalkenyl is, for example, a monocyclic hydrocarbon ring, such as cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl.

[0344] The term "C3-C6-cycloalkoxy" refers to a saturated monovalent radical of the formula (C3-C6-cycloalkyl)-O-, wherein the term "C3-C6-cycloalkyl" is as defined above, for example cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or cyclohexyloxy.

[0345] The term "4- to 7-membered heterocycloalkyl" refers to a monocyclic saturated heterocycle having a total of 4, 5, 6 or 7 ring atoms, including one or two identical or different ring heteroatoms selected from N, O and S.

[0346] The heteroalkyl group (not limited thereto) may be a 4-membered ring, such as azetidinyl, oxetanyl, or thietanyl; or a 5-membered ring, such as tetrahydrofuranyl, 1,3-dioxolanyl, thiolanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1,1-dioxathiolanyl, 1,2-oxazolidinyl, 1,3-oxazolidinyl, or 1,3-thiazolidinyl; or a 6-membered ring, such as tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, 1,3-dioxanyl, 1,4-dioxanyl, or 1,2-oxazinyl; or a 7-membered ring, such as azepanyl, 1,4-diazepanyl, or 1,4-oxazepanyl.

[0347] The term "5- to 7-membered heterocycloalkenyl" refers to a monocyclic, unsaturated, non-aromatic heterocycle having a total of 5, 6 or 7 ring atoms, containing one or two double bonds and one or two identical or different ring heteroatoms selected from N, O and S.

[0348] The heterocycloalkenyl group is, for example, 4H-pyranyl, 2H-pyranyl, 2,5-dihydro-1H-pyrrolyl, [1,3]dioxolyl, 4H-[1,3,4]thiadiazinyl, 2,5-dihydrofuranyl, 2,3-dihydrofuranyl, 2,5-dihydrothienyl, 2,3-dihydrothienyl, 4,5-dihydrooxazolyl or 4H-[1,4]thiazinyl.

[0349] The term "(4- to 7-membered heterocycloalkyl)oxy" refers to a monocyclic saturated heterocycloalkyl group of the formula (4- to 7-membered heterocycloalkyl)-O-, wherein the term "4- to 7-membered heterocycloalkyl" is as defined above.

[0350] The term "nitrogen-containing 4- to 7-membered heterocycloalkyl" refers to a monocyclic saturated heterocycle having a total of 4, 5, 6 or 7 ring atoms, including one ring nitrogen atom and optionally one additional ring heteroatom selected from N, O and S.

[0351] The nitrogen-containing 4- to 7-membered heterocycloalkyl group is not limited thereto and may be a 4-membered ring, such as an azetidinyl group; or a 5-membered ring, such as a pyrrolidinyl group, an imidazolidinyl group, a pyrazolidinyl group, a 1,2-oxazolidinyl group, a 1,3-oxazolidinyl group or a 1,3-thiazolidinyl group; or a 6-membered ring, such as a piperidinyl group, a morpholinyl group, a thiomorpholinyl group, a piperazinyl group or a 1,2-oxazinyl group; or a 7-membered ring, such as an azepanyl group, a 1,4-diazepanyl group or a 1,4-oxazepanyl group.

[0352] The term "heteroaryl" refers to a monovalent monocyclic or bicyclic aromatic ring having 5, 6, 8, 9 or 10 ring atoms (a "5- to 10-membered heteroaryl" group), which contains at least one ring heteroatom and optionally one, two or three further ring heteroatoms selected from N, O and / or S, and which is bonded via a ring carbon atom.

[0353] The heteroaryl group may be a 5-membered heteroaryl group, such as thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl or tetrazolyl; or a 6-membered heteroaryl group, such as pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl; or a 9-membered heteroaryl group, such as benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzothiazolyl, benzotriazolyl, thiazolopyridinyl, indazolyl, indolyl, isoindolyl, indolizinyl or purinyl; or a 10-membered heteroaryl group, such as quinolinyl, quinazolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinoxalinyl or pteridinyl.

[0354] In general, unless otherwise indicated, a heteroaryl or heteroarylene group includes all possible isomeric forms thereof, for example, tautomers and positional isomers with respect to the point of attachment to the rest of the molecule. Thus, for some illustrative, non-limiting examples, the term pyridyl includes pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl; or the term thienyl includes thien-2-yl and thien-3-yl.

[0355] As used herein, for example in the context of the definition of “C1-C6-alkyl”, “C1-C6-haloalkyl”, “C1-C6-hydroxyalkyl”, “C1-C6-alkoxy” or “C1-C6-haloalkoxy”, the term “C1-C6” refers to an alkyl group having a finite number of carbon atoms from 1 to 6, i.e., 1, 2, 3, 4, 5 or 6 carbon atoms.

[0356] Furthermore, the term "C3-C8" as used herein, for example in the context of the definition of "C3-C6-cycloalkyl", refers to a cycloalkyl group having a finite number of carbon atoms of 3 to 6, i.e. 3, 4, 5 or 6 carbon atoms.

[0357] When a numerical range is given, that range includes every number and sub-range within that range.

[0358] For example:

[0359] "C1-C6" includes C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5 and C5-C6;

[0360] "C2-C6" includes C2, C3, C4, C5, C6, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5 and C5-C6;

[0361] “C3-C6” includes C3, C4, C5, C6, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6;

[0362] As used herein, the term "leaving group" refers to an atom or group of atoms that is substituted as a stable species in a chemical reaction, which carries bonding electrons. In particular, such leaving groups are selected from the group consisting of: halides, in particular fluorides, chlorides, bromides or iodides, (methylsulfonyl)oxy, [(trifluoromethyl)sulfonyl]oxy, [(nonafluorobutyl)sulfonyl]oxy, (phenylsulfonyl)oxy, [(4-methylphenyl)sulfonyl]oxy, [(4-bromophenyl)sulfonyl]oxy, [(4-nitrophenyl)sulfonyl]oxy, [(2-nitrophenyl)sulfonyl]oxy, [(4-isopropylphenyl)sulfonyl]oxy, [(2,4,6-triisopropylphenyl)sulfonyl]oxy, [(2,4,6-trimethylphenyl)sulfonyl]oxy, [(4-tert-butylphenyl)sulfonyl]oxy and [(4-methoxyphenyl)sulfonyl]oxy.

[0363] The compounds of general formula (I) may exist as isotopic variations. Therefore, the present invention includes one or more isotopic variations of the compounds of general formula (I), in particular deuterated compounds of general formula (I).

[0364] The term "isotopic variant" of a compound or agent is defined as a compound that exhibits an unnatural ratio of one or more isotopes that constitute the compound.

[0365] The term "isotopic variation of a compound of formula (I)" is defined as a compound of formula (I) that exhibits an unnatural ratio of one or more isotopes constituting the compound.

[0366] The expression "unnatural proportion" refers to a proportion of this isotope that is higher than its natural abundance. The natural abundance of the isotopes used in this case is described in "Isotopic Compositions of the Elements 1997", Pure Appl. Chem., 70(1), 217-235, 1998.

[0367] Examples of such isotopes include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, e.g. 2 H (deuterium), 3 H (tritium), 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 32 P. 33 P. 33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 125 I. 129 I and 131 I.

[0368] For the treatment and / or prevention of the diseases specified herein, isotopic variations of the compounds of formula (I) preferably contain deuterium ("deuterated compounds of formula (I)"). Isotopic variations of the compounds of formula (I) (in which one or more radioactive isotopes are incorporated, e.g. 3 H or 14 C) are useful, for example, in drug and / or substrate tissue distribution studies. These isotopes are particularly preferred because they are easy to bind and easy to detect. Positron emitting isotopes such as 18 F or 11 C can be incorporated into the compounds of formula (I). These isotopic variants of the compounds of formula (I) can be used for in vivo imaging applications. 13 Compound C can be used for mass spectrometry analysis in preclinical or clinical research settings.

[0369] Isotopic variants of compounds of formula (I) can generally be prepared by methods known to those skilled in the art, such as those described in the schemes and / or examples herein, by replacing an isotopic variant of the reagent with a reagent, preferably replacing a deuterated reagent. Depending on the desired deuteration site, in some cases, deuterium from D2O can be directly incorporated into the compound or incorporated into a reagent that can be used to synthesize such compounds. Deuterium gas is also a useful reagent for incorporating deuterium into molecules. Catalytic deuteration of olefinic and acetylenic bonds is a rapid way to incorporate deuterium. Metal catalysts (i.e., Pd, Pt, and Rh) in the presence of deuterium gas can be used to directly exchange deuterium for hydrogen in hydrocarbon-containing functional groups. Various deuterated reagents and synthetic building blocks are commercially available from the following companies, such as C / D / N Isotopes, Quebec, Canada; Cambridge Isotope Laboratories Inc., Andover, MA, USA; and CombiPhos Catalysts, Inc., Princeton, NJ, USA.

[0370] The term "deuterium-containing compound of formula (I)" is defined as a compound of formula (I) wherein one or more hydrogen atoms are replaced by one or more deuterium atoms, and wherein the deuterium abundance at each deuterated position of the compound of formula (I) is higher than the natural abundance of deuterium, which is about 0.015%. In particular, in a deuterium-containing compound of formula (I), the deuterium abundance at each deuterated position of the compound of formula (I) is higher than 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80% at said position, preferably higher than 90%, 95%, 96% or 97%, even more preferably higher than 98% or 99%. It will be understood that the deuterium abundance at each deuterated position is independent of the deuterium abundance at other deuterated positions.

[0371] The selective incorporation of one or more deuterium atoms into compounds of general formula (I) can alter the physicochemical properties (e.g. acidity [CL Perrin et al., J. Am. Chem. Soc., 2007, 129, 4490], basicity [CL Perrin et al., J. Am. Chem. Soc., 2005, 127, 9641], lipophilicity [B. Testa et al., Int. J. Pharm., 1984, 19 (3), 271]) and / or the metabolic profile of the molecule and can result in a change in the ratio of parent compound to metabolite or in the amount of metabolite formed. Such changes may confer certain therapeutic advantages and may therefore be preferred in certain circumstances. It has been reported that in cases where the ratio of metabolites is altered, the rate of metabolism and metabolic conversion is reduced (AEMutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102). Exposure to these changes in the parent drug and metabolites may have an important impact on the pharmacodynamics, tolerability and efficacy of the deuterated compounds of general formula (I). In some cases, deuterium substitution reduces or eliminates the formation of undesirable or toxic metabolites and enhances the formation of desired metabolites (e.g., nevirapine: AM Sharma et al., Chem. Res. Toxicol., 2013, 26, 410; Efavirenz: AEMutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102). In other cases, the main effect of deuteration is to reduce systemic clearance. As a result, the biological half-life of the compound is increased. Potential clinical benefits will include the ability to maintain similar systemic exposure with reduced peak levels and increased trough levels. This may result in reduced side effects and improved efficacy based on the pharmacokinetic / pharmacodynamic relationship of a specific compound. ML-337 (CJ Wenthur et al., J. Med. Chem., 2013, 56, 5208) and Odanacatib (Odanacatib) (K. Kassahun et al., WO 2012 / 112363) are examples of this deuterium effect. Other cases have also been reported, in which reduced metabolic rate leads to increased drug exposure without changing systemic clearance (e.g., rofecoxib (Rofecoxib): F. Schneider et al., Arzneim. Forsch. / Drug. Res., 2006, 56, 295; Telaprevir (Telaprevir): F. Maltais et al., J. Med. Chem., 2009, 52, 7993). Deuterated drugs showing this effect may need to reduce dosage (e.g., less dosage or lower dosage to achieve the desired effect) and / or may produce a lower metabolite load.

[0372] The compound of general formula (I) can have the potential attack site of multiple metabolism.In order to optimize the above-mentioned impact on physicochemical property and metabolic characteristics, the deuterated compound of the general formula (I) of one or more deuterium-hydrogen exchanges with a particular pattern can be selected. Especially, the deuterium atom of the deuterated compound of general formula (I) is connected to carbon atom and / or is positioned at those positions of general formula (I) compound, which is a metabolic enzyme, for example the attack site of cytochrome P450.

[0373] In a further embodiment of the invention, it relates to deuterium-containing compounds of the general formula (I) having 1, 2, 3 or 4 deuterium atoms, in particular having 1, 2 or 3 deuterium atoms.

[0374] When the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like is used herein, this also refers to a single compound, salt, polymorph, isomer, hydrate, solvate and the like.

[0375] By "stable compound" or "stable structure" is meant a compound that is sufficiently robust that it can be isolated to a useful degree of purity from a reaction mixture, and formulated into an efficacious therapeutic agent.

[0376] The compounds of the present invention optionally contain one or more asymmetric centers, depending on the desired location and nature of the various substituents. One or more asymmetric carbon atoms may be present in the (R) or (S) configuration, which may result in racemic mixtures in the case of a single asymmetric center and diastereomeric mixtures in the case of multiple asymmetric centers. In some cases, asymmetry may also exist due to restricted rotation around a given bond (e.g., a central bond adjacent to two substituted aromatic rings of a given compound).

[0377] Preferred compounds are those that produce more desirable biological activity. Isolation, pure or partially purified isomers and stereoisomers or racemates or diastereomeric mixtures of the compounds of the invention are also included within the scope of the present invention. The purification and separation of these materials can be accomplished by standard techniques known in the art.

[0378] Preferred compounds are those that produce more desirable biological activity. Isolation, pure or partially purified isomers and stereoisomers or racemates or diastereomeric mixtures of the compounds of the invention are also included within the scope of the present invention. The purification and separation of these materials can be accomplished by standard techniques known in the art.

[0379] Optical isomers can be obtained by splitting racemic mixtures according to conventional methods, for example, by forming diastereomeric salts or forming covalent diastereomers using optically active acids or bases. Examples of suitable acids are tartaric acid, diacetyltartaric acid, ditoluoyltartaric acid and camphorsulfonic acid. A mixture of diastereoisomers can be separated into their respective diastereomers based on their physical and / or chemical differences by methods known in the art (for example, by chromatography or fractional crystallization). The optically active base or acid is then released from the separated diastereomeric salts. The different methods for separating optical isomers involve using chiral chromatography (for example, using an HPLC column of a chiral phase), with or without conventional derivatization, preferably to separate enantiomers to the greatest extent possible. Suitable HPLC columns using chiral phases are commercially available, such as those manufactured by Daicel, such as Chiracel OD and Chiracel OJ, and many others, which are all conventionally selectable. Enzymatic separation - with or without derivatization - is also useful. The optically active compounds of the present invention can also be obtained by chiral synthesis using optically active starting materials.

[0380] In order to distinguish different types of isomers from each other, reference is made to IUPAC Rules Section E (Pure Appl Chem 45, 11 30, 1976).

[0381] The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of such stereoisomers (e.g., (R) or (S) isomers in any ratio). Isolation of single stereoisomers (e.g., single enantiomers or single diastereomers) of the compounds of the present invention can be achieved by any suitable state of the art method, such as chromatography, in particular chiral chromatography.

[0382] In addition, the compounds of the present invention may exist as tautomers. For example, the compounds of the present invention may contain an amide moiety and may exist as an amide, or an imidic acid, or even a mixture of any amount of the two tautomers, i.e.:

[0383]

[0384] The present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers in any ratio.

[0385] Additionally, the compounds of the present invention may exist as N-oxides, which are defined as at least one nitrogen atom of the compounds of the present invention being oxidized. The present invention includes all such possible N-oxides.

[0386] The present invention also relates to useful forms of the compounds of the present invention, such as metabolites, hydrates, solvates, prodrugs, salts (particularly pharmaceutically acceptable salts) and / or coprecipitates.

[0387] The compounds of the present invention may exist as hydrates or solvates, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol, for example as structural elements of the compound's crystal lattice. The amount of polar solvent (in particular water) may be present in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, for example, hydrates, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates are possible. The present invention includes all such hydrates or solvates.

[0388] Furthermore, the compounds of the present invention may exist in free form, for example as a free base, or as a free acid, or as a zwitterion, or in the form of a salt. The salt may be any salt, organic or inorganic addition salt, in particular any pharmaceutically acceptable organic or inorganic addition salt, which is conventionally used in pharmacy or for example for isolating or purifying the compounds of the present invention.

[0389] The term "pharmaceutically acceptable salt" refers to an inorganic or organic acid addition salt of a compound of the present invention. For example, see SM Berge et al. "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1-19.

[0390] Suitable pharmaceutically acceptable salts of the compounds of the invention may be acid addition salts of compounds of the invention which carry nitrogen atoms in the chain or ring, for example, which have sufficient basicity, such as acid addition salts with inorganic acids or "mineral acids" such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, disulfuric acid, phosphoric acid or nitric acid; or with organic acids such as formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyl)-benzoic acid, camphoric acid, carnitine. Cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxy-2-naphthoic acid, nicotinic acid, pamoic acid, pectic acid, 3-phenylpropionic acid, pivalic acid, 2-hydroxyethanesulfonic acid, itaconic acid, trifluoromethanesulfonic acid, dodecylsulfuric acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptonic acid, glycerophosphate, aspartic acid, sulfosalicylic acid, or thiocyanic acid.

[0391] In addition, another suitable pharmaceutically acceptable salt with sufficient acidity of the compound of the present invention is an alkali metal salt, such as a sodium salt or a potassium salt, an alkaline earth metal salt, such as a calcium salt, a magnesium salt or a strontium salt, or an aluminum salt or a zinc salt, or a hydroxymethylamine, ... ammonium salts of organic primary, secondary or tertiary amines such as 2-amino-1,3-propanediol, 3-amino-1,2-propanediol, 4-amino-1,2,3-butanetriol, or salts of quaternary ammonium ions having 1 to 20 carbon atoms (e.g., tetramethylammonium, tetraethylammonium, tetra(n-propyl)ammonium, tetra(n-butyl)ammonium, N-benzyl-N,N,N-trimethylammonium, choline or benzalkonium chloride).

[0392] Those skilled in the art will further recognize that acid addition salts of the claimed compounds can be prepared by any of a variety of known methods by reacting the compound with a suitable inorganic or organic acid. Alternatively, alkali metal salts and alkaline earth metal salts of the acidic compounds of the present invention can be prepared by reacting the compounds of the present invention with a suitable base by various known methods.

[0393] The present invention includes all possible salts of the compounds of the present invention as a single salt, or as any mixture of said salts in any ratio.

[0394] In this text (especially in the "Experimental Section"), for the synthesis of intermediates and examples of the present invention, when the compounds are mentioned as salt forms with the corresponding bases or acids, the exact stoichiometric composition of said salt forms obtained by the corresponding preparation and / or purification processes is in most cases unknown.

[0395] Unless otherwise indicated, suffixes in chemical names or formulas relating to salts, such as "hydrochloride", "trifluoroacetate", "sodium salt" or "×HCl", "×CF3COOH", "×Na + ” etc. denotes a salt form, the stoichiometry of which is unspecified.

[0396] This applies analogously to the case where synthetic intermediates or example compounds or salts thereof have been obtained by the described preparation and / or purification processes as solvates (eg hydrates) of (if defined) unknown stoichiometric composition.

[0397] Furthermore, the present invention includes all possible crystalline forms or polymorphs of the compounds of the present invention, either as a single polymorph or as a mixture of more than one polymorph in any ratio.

[0398] Furthermore, the present invention also includes prodrugs of the compounds of the present invention. The term "prodrug" herein means a compound which itself may be biologically active or inactive, but which can be converted (eg metabolized or hydrolyzed) into a compound of the present invention during its residence time in the body.

[0399] The present invention further includes all possible cyclodextrin inclusion compounds, ie α-, β- or γ-cyclodextrin, hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin.

[0400] According to a second embodiment of the first aspect, the present invention covers compounds of the above-mentioned general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[0401] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 The group,

[0402] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[0403] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[0404] and

[0405] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0406] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C6-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0407] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[0408] -(CH2)3-, -CH2-CH(OH)-CH2-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-CH(CH3)-O-, -CH2-O-CH2-, -O- (CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O-, -OC(CH3)2-O-, -O-(CH2)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-(C(CH2)3)-、-N(R 18 )-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O)-N(R 18 )-,

[0409] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0410] and

[0411] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0412] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0413] and

[0414] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[0415] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0416] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0417] and

[0418] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0419] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0420] and

[0421] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0422] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0423] and

[0424] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0425] and

[0426] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0427] and

[0428] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0429] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0430] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0431] C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2 alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0432] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0433] and

[0434] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0435] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R10 ) and oxo,

[0436] and

[0437] wherein the C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0438] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0439] and

[0440] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0441] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0442] and

[0443] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a

[0444] From the following groups:

[0445] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0446] and

[0447] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0448] and

[0449] wherein the C2-C4-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[0450] and

[0451] wherein the C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl and C1-C4-haloalkyl,

[0452] and

[0453] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0454] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0455] R 4 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0456] C1-C6-alkyl, C1-C6-haloalkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1-C5-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, -O-(C1-C4-alkyl)-C(=O)OR 15 、-O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, -S(=O)R 14 、-S(=O)2R 14 , cyano, nitro, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-N(R 16 )(R 20 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0457] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0458] and

[0459] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0460] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0461] and

[0462] wherein the C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0463] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0464] and

[0465] The 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0466] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0467] and

[0468] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0469] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0470] and

[0471] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0472] and

[0473] wherein the C1-C4-alkoxy group is optionally substituted by an oxiran-2-yl group,

[0474] and

[0475] wherein the C3-C5-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0476] and

[0477] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0478] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0479] R 5 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0480] C1-C5-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2 alkoxy)-(C2-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0481] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0482] and

[0483] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0484] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0485] and

[0486] wherein the C1-C5-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0487] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0488] and

[0489] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0490] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0491] and

[0492] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0493] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0494] and

[0495] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0496] and

[0497] wherein the C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0498] and

[0499] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0500] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0501] R 6 represents a hydrogen atom or a fluorine atom, or a radical selected from the group consisting of C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, hydroxy and oxo,

[0502] R 7 represents a hydrogen atom or a halogen atom, or a radical selected from the group consisting of C1-C4-alkyl, C1-C4-alkoxy, hydroxy and cyano,

[0503] R 8 represents a group selected from methyl and ethyl,

[0504] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a group selected from:

[0505] C1-C4-alkyl, C2-C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkoxy)-(C2-C4-alkyl)-, C3-C4-cycloalkyl and C2-C4-haloalkyl,

[0506] or

[0507] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[0508] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxyl and oxo,

[0509] or

[0510] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[0511] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, hydroxyl and oxo,

[0512] R 11 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, phenyl and 5- or 6-membered heteroaryl,

[0513] wherein the phenyl and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0514] R 12 represents a hydrogen atom or a C1-C4-alkyl group,

[0515] R 13 represents a hydrogen atom or a radical selected from C1-C4-alkyl, phenyl and 5- or 6-membered heteroaryl,

[0516] wherein the phenyl and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0517] R 14 represents a radical selected from the group consisting of C1-C4-alkyl, C1-C4-haloalkyl, C3-C5-cycloalkyl, phenyl and 5- or 6-membered heteroaryl,

[0518] wherein the phenyl and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0519] R 15 represents a hydrogen atom or a C1-C4-alkyl group,

[0520] R 16 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C3-C4-cycloalkyl and C2-C4-haloalkyl,

[0521] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[0522] wherein the 4- to 7-membered heterocycloalkyl is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxyl and oxo,

[0523] and

[0524] The 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[0525] R 18 represents a hydrogen atom or a group selected from methyl and ethyl,

[0526] R 19 represents a hydrogen atom or a group selected from methyl and ethyl,

[0527] R 20 represents a (4- to 7-membered heterocycloalkyl)-(C1-C4-alkyl)- group,

[0528] wherein the (4- to 7-membered heterocycloalkyl) part of the group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxyl and oxo,

[0529] m represents an integer selected from 1, 2 and 3,

[0530] and

[0531] n represents an integer selected from 1, 2 and 3.

[0532] According to a variant of the second embodiment of the first aspect, the present invention covers compounds of the above general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[0533] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 The group,

[0534] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[0535] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[0536] and

[0537] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0538] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C6-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0539] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[0540] -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O-, and -OC(CH2)2-O-,

[0541] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0542] and

[0543] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0544] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0545] and

[0546] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[0547] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0548] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0549] and

[0550] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0551] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0552] and

[0553] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0554] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0555] and

[0556] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0557] and

[0558] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0559] and

[0560] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0561] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0562] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0563] C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2 alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0564] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0565] and

[0566] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0567] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0568] and

[0569] wherein the C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0570] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0571] and

[0572] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0573] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0574] and

[0575] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a

[0576] From the following groups:

[0577] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0578] and

[0579] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0580] and

[0581] wherein the C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0582] and

[0583] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0584] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0585] R 4 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0586] C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1-C5-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0587] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0588] and

[0589] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0590] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0591] and

[0592] wherein the C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0593] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0594] and

[0595] The 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0596] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0597] and

[0598] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0599] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0600] and

[0601] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0602] and

[0603] wherein the C3-C5-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0604] and

[0605] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0606] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0607] R 5 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0608] C1-C5-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2 alkoxy)-(C2-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[0609] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0610] and

[0611] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0612] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10) and oxo,

[0613] and

[0614] wherein the C1-C5-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0615] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0616] and

[0617] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0618] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[0619] and

[0620] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0621] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0622] and

[0623] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0624] and

[0625] wherein the C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[0626] and

[0627] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0628] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R9 )(R 10 ),

[0629] R 6 represents a hydrogen atom or a fluorine atom, or a radical selected from the group consisting of C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, hydroxy and oxo,

[0630] R 7 represents a hydrogen atom or a halogen atom, or a radical selected from the group consisting of C1-C4-alkyl, C1-C4-alkoxy, hydroxy and cyano,

[0631] R 8 represents a group selected from methyl and ethyl,

[0632] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a group selected from:

[0633] C1-C4-alkyl, (C1-C4-alkoxy)-(C2-C4-alkyl)-, C3-C4-cycloalkyl and C2-C4-haloalkyl,

[0634] or

[0635] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[0636] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxyl and oxo,

[0637] or

[0638] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[0639] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, hydroxyl and oxo,

[0640] R 11 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, phenyl and 5- or 6-membered heteroaryl,

[0641] wherein the phenyl and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0642] R 12 represents a hydrogen atom or a C1-C4-alkyl group,

[0643] R 13 represents a hydrogen atom or a radical selected from C1-C4-alkyl, phenyl and 5- or 6-membered heteroaryl,

[0644] wherein the phenyl and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0645] R 14 represents a radical selected from the group consisting of C1-C4-alkyl, C1-C4-haloalkyl, C3-C5-cycloalkyl, phenyl and 5- or 6-membered heteroaryl,

[0646] wherein the phenyl and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0647] R 15 represents a hydrogen atom or a C1-C4-alkyl group,

[0648] R 16 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C3-C4-cycloalkyl and C2-C4-haloalkyl,

[0649] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[0650] wherein the 4- to 7-membered heterocycloalkyl is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxyl and oxo,

[0651] and

[0652] The 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[0653] and

[0654] n represents an integer selected from 1, 2 and 3.

[0655] According to a third embodiment of the first aspect, the present invention covers compounds of the above-mentioned general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[0656] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 The group,

[0657] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[0658] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[0659] and

[0660] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0661] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 ) 2, 4 to 7 membered heterocycloalkyl, phenyl and 5 or 6 membered heteroaryl,

[0662] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[0663] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-(C(CH2)3)-、-N(R 18 )-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O)-N(R 18 )-,

[0664] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0665] and

[0666] wherein the C1-C4-alkoxy group is optionally substituted by a group selected from phenyl and 4- to 7-membered heterocycloalkyl,

[0667] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0668] and wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or from a C1-C2-alkyl group, a C1-C2-haloalkyl group, a cyano group, a hydroxyl group, a C1-C2-alkoxy group, a C3-C4-cycloalkyl group and -N(R 9 )(R 10 ),

[0669] and

[0670] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0671] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0672] C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0673] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0674] and

[0675] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0676] and

[0677] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0678] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0679] and

[0680] wherein the 4 to 7 membered heterocycloalkyl is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0681] and

[0682] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0683] and

[0684] wherein the C2-C4-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[0685] and

[0686] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a radical selected from C1-C4-alkyl and C1-C4-haloalkyl,

[0687] R 4 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0688] C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, -O-(C1-C4-alkyl)-C(=O)OR 15 、-O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, nitro, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-N(R 16 )(R 20 ),-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0689] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0690] and

[0691] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0692] and

[0693] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0694] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0695] and

[0696] wherein the 4 to 7 membered heterocycloalkyl is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0697] and wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy,

[0698] and

[0699] wherein the C1-C4-alkoxy group is optionally substituted by an oxiran-2-yl group,

[0700] and

[0701] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0702] and

[0703] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0704] R 5 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0705] C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy,

[0706] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0707] and

[0708] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0709] and

[0710] wherein the C1-C5-alkyl, C1-C4-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[0711] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0712] and

[0713] wherein the 4 to 7 membered heterocycloalkyl is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0714] and

[0715] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or from a C1-C2-alkyl group, a C1-C2-haloalkyl group, a cyano group, a hydroxyl group, a C1-C2-alkoxy group, a C3-C4-cycloalkyl group and -N(R 9 )(R 10 ),

[0716] and

[0717] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0718] and

[0719] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0720] R 6 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, hydroxy and oxo,

[0721] R 7 represents a hydrogen atom or a halogen atom or a radical selected from C1-C4-alkyl, C1-C4-alkoxy and hydroxy,

[0722] R 8 represents a group selected from methyl and ethyl,

[0723] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a member selected from the group consisting of C1-C4-alkyl, C2-C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkoxy)-(C2-C4-alkyl)- and C3-C4-cycloalkyl,

[0724] or

[0725] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[0726] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxyl and oxo,

[0727] or

[0728] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[0729] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, hydroxyl and oxo,

[0730] R 11represents a hydrogen atom or a radical selected from C1-C4-alkyl and C1-C4-haloalkyl,

[0731] R 12 represents a hydrogen atom,

[0732] R 13 represents phenyl,

[0733] R 14 represents a group selected from C1-C4-alkyl and phenyl,

[0734] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0735] R 15 represents a hydrogen atom or a C1-C4-alkyl group,

[0736] and

[0737] R 16 represents a hydrogen atom or a C1-C4-alkyl group,

[0738] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[0739] wherein the 4- to 7-membered heterocycloalkyl radical is optionally substituted one or two times by C1-C4-alkyl,

[0740] and

[0741] wherein the 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[0742] R 18 represents a hydrogen atom or a methyl group,

[0743] R 19 represents a hydrogen atom or a methyl group,

[0744] R 20 represents a (4- to 7-membered heterocycloalkyl)-(C1-C4-alkyl)- group,

[0745] wherein the (4- to 7-membered heterocycloalkyl) part of the group is optionally substituted one or two times by C1-C4-alkyl,

[0746] m represents an integer selected from 1 and 2,

[0747] and

[0748] n represents an integer selected from 1, 2 and 3.

[0749] According to a variant of the third embodiment of the first aspect, the present invention covers compounds of the above general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[0750] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 The group,

[0751] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[0752] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[0753] and

[0754] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0755] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[0756] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group,

[0757] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or from a C1-C2-alkyl group, a C1-C2-haloalkyl group, a cyano group, a hydroxyl group, a C1-C2-alkoxy group, a C3-C4-cycloalkyl group and -N(R 9 )(R 10 ),

[0758] R3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0759] C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 ),-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0760] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0761] and

[0762] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0763] and

[0764] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0765] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0766] and

[0767] wherein the 4 to 7 membered heterocycloalkyl is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0768] and

[0769] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0770] and

[0771] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0772] R 4 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0773] C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, -N(R 9 )(R 10 )、-N(R 16 )(R 17 ),-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0774] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0775] and

[0776] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0777] and

[0778] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0779] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0780] and

[0781] wherein the 4 to 7 membered heterocycloalkyl is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0782] and wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy,

[0783] and

[0784] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0785] and

[0786] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0787] R 5 represents a hydrogen atom or a halogen atom or a group selected from the following:

[0788] C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy,

[0789] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0790] and

[0791] wherein the 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0792] and

[0793] wherein the C1-C5-alkyl, C1-C4-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl groups,

[0794] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0795] and

[0796] wherein the 4 to 7 membered heterocycloalkyl is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo groups,

[0797] and

[0798] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or from a C1-C2-alkyl group, a C1-C2-haloalkyl group, a cyano group, a hydroxyl group, a C1-C2-alkoxy group, a C3-C4-cycloalkyl group and -N(R 9 )(R 10 ),

[0799] and

[0800] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0801] and

[0802] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0803] R 6 represents a hydrogen atom or a radical selected from C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, hydroxy and oxo,

[0804] R 7represents a hydrogen atom or a halogen atom or a group selected from C1-C4-alkyl and hydroxyl,

[0805] R 8 represents a group selected from methyl and ethyl,

[0806] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a C1-C4-alkyl group,

[0807] or

[0808] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[0809] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxyl and oxo,

[0810] or

[0811] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[0812] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, hydroxyl and oxo,

[0813] R 11 represents a hydrogen atom or a C1-C4-haloalkyl group,

[0814] R 12 represents hydrogen atoms,

[0815] R 13 represents phenyl,

[0816] R 14 represents a group selected from C1-C4-alkyl and phenyl,

[0817] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or selected from C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxyl, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[0818] R 15 represents a hydrogen atom or a C1-C4-alkyl group,

[0819] R16 represents a hydrogen atom or a C1-C4-alkyl group,

[0820] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[0821] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one or two times by C1-C4-alkyl,

[0822] and

[0823] wherein the 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[0824] and

[0825] n represents an integer selected from 1, 2 and 3.

[0826] According to a fourth embodiment of the first aspect, the present invention covers compounds of the above-mentioned general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[0827] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2,

[0828] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[0829] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[0830] and

[0831] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0832] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 ) 2, 4 to 7 membered heterocycloalkyl, phenyl and 5 or 6 membered heteroaryl,

[0833] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[0834] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-(C(CH2)3)-、-N(R 18 )-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O)-N(R 18 )-, wherein the 4- to 7-membered heterocycloalkyl is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl,

[0835] and

[0836] wherein the C1-C4-alkoxy group is optionally substituted by a group selected from 4- to 7-membered heterocycloalkyl and phenyl,

[0837] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0838] and

[0839] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy,

[0840] R 3 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0841] C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0842] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0843] and

[0844] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0845] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0846] and

[0847] wherein the C3-C4-cycloalkyl radical is optionally substituted once or twice by cyano,

[0848] and

[0849] wherein the C2-C4-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[0850] and

[0851] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a radical selected from C1-C4-alkyl and C1-C4-haloalkyl,

[0852] R 4 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0853] C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-,

[0854] -O-(C1-C4-alkyl)-C(=O)OR 15 、-O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, -S(=O)2R 14, cyano, nitro, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-N(R 16 )(R 20 ),-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0855] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0856] and

[0857] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0858] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0859] and

[0860] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0861] and

[0862] wherein the C1-C4-alkoxy group is optionally substituted by an oxiran-2-yl group,

[0863] and

[0864] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0865] R 5 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0866] C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 ), 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy,

[0867] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0868] R 6 represents a hydrogen atom or a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl,

[0869] R 7 represents a hydrogen atom or a halogen atom, or a radical selected from the group consisting of C1-C4-alkyl, C1-C4-alkoxy and hydroxy,

[0870] R 8 represents a group selected from methyl and ethyl,

[0871] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a radical selected from the group consisting of C1-C4-alkyl, C2-C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkoxy)-(C2-C4-alkyl)- and C3-C4-cycloalkyl,

[0872] or

[0873] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[0874] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, hydroxyl and oxo,

[0875] or

[0876] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[0877] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one or two times by C1-C4-alkyl,

[0878] R 11 represents a group selected from C1-C4-alkyl and C1-C4-haloalkyl,

[0879] R 12 represents hydrogen atoms,

[0880] R 13 represents phenyl,

[0881] R 14 represents a group selected from C1-C4-alkyl and phenyl,

[0882] R 15represents a hydrogen atom or a C1-C4-alkyl group,

[0883] R 16 represents a hydrogen atom or a C1-C4-alkyl group,

[0884] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[0885] wherein the 4- to 7-membered heterocycloalkyl radical is optionally substituted one or two times by C1-C4-alkyl,

[0886] and

[0887] wherein the 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[0888] R 18 represents a hydrogen atom or a methyl group,

[0889] R 19 represents a hydrogen atom or a methyl group,

[0890] R 20 represents a (4- to 7-membered heterocycloalkyl)-(C1-C4-alkyl)- group,

[0891] wherein the (4- to 7-membered heterocycloalkyl) part of the group is optionally substituted one or two times by C1-C4-alkyl,

[0892] m represents an integer selected from 1 and 2,

[0893] and

[0894] n represents an integer selected from 1, 2 and 3.

[0895] According to a variant of the fourth embodiment of the first aspect, the present invention covers compounds of the above general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[0896] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2,

[0897] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[0898] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[0899] and

[0900] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[0901] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[0902] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group,

[0903] R 3 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0904] C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 ), 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0905] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0906] and

[0907] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0908] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0909] and

[0910] wherein the C3-C4-cycloalkyl radical is optionally substituted once or twice by cyano,

[0911] and

[0912] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice by a halogen atom,

[0913] R 4 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0914] C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, -N(R 9 )(R 10 )、-N(R 16 )(R 17 ),-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0915] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0916] and

[0917] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0918] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0919] and

[0920] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0921] and

[0922] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0923] R 5 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0924] C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 ), 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy,

[0925] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0926] R 6 represents a hydrogen atom or a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl,

[0927] R 7 represents a hydrogen atom or a halogen atom, or a radical selected from C1-C4-alkyl and hydroxyl,

[0928] R 8 represents a group selected from methyl and ethyl,

[0929] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a C1-C4-alkyl group,

[0930] or

[0931] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[0932] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, hydroxyl and oxo,

[0933] or

[0934] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[0935] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one or two times by C1-C4-alkyl,

[0936] R 11 represents a C1-C4-haloalkyl group,

[0937] R 12 represents hydrogen atoms,

[0938] R 13 represents phenyl,

[0939] R 14represents a group selected from C1-C4-alkyl and phenyl,

[0940] R 16 represents a hydrogen atom or a C1-C4-alkyl group,

[0941] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[0942] wherein the 4- to 7-membered heterocycloalkyl radical is optionally substituted one or two times by C1-C4-alkyl,

[0943] and

[0944] wherein the 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[0945] and

[0946] n represents an integer selected from 1, 2 and 3. According to a fifth embodiment of the first aspect, the present invention covers compounds of the above-mentioned general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[0947] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2,

[0948] R 2 represents a group selected from phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl,

[0949] wherein the 5- to 10-membered heteroaryl group is selected from the following groups:

[0950] pyrazolyl, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1,3-thiazolyl, pyridyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, 1,3-benzoxazolyl, indazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, and 1,3-thiazolo[5,4-b]pyridinyl, and

[0951] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[0952] and

[0953] wherein phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or from the following groups:

[0954] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 ) 2, 4 to 7 membered heterocycloalkyl, phenyl and pyridyl,

[0955] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[0956] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O)-C(C H3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2-C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O)-N(CH3)-,

[0957] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0958] and

[0959] wherein the C1-C4-alkoxy group is optionally substituted by a group selected from 4- to 7-membered heterocycloalkyl and phenyl,

[0960] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0961] and

[0962] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy,

[0963] R 3represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0964] C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0965] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0966] and

[0967] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0968] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0969] and

[0970] wherein the C3-C4-cycloalkyl radical is optionally substituted once or twice by cyano,

[0971] and

[0972] wherein the C2-C4-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[0973] and

[0974] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice by a halogen atom or a radical selected from the group consisting of C1-C4-alkyl and C1-C4-haloalkyl,

[0975] R 4 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0976] C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, -O-CH2-C(=O)OR15 、-O-CH2-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, nitro, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-N(R 16 )(R 20 ),-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[0977] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[0978] and

[0979] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[0980] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0981] and

[0982] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[0983] and

[0984] wherein the C1-C4-alkoxy group is optionally substituted by an oxiran-2-yl group,

[0985] and

[0986] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[0987] R 5 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[0988] C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14, cyano, hydroxyl, -N(R 9 )(R 10 ), 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy,

[0989] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[0990] R 6 represents a hydrogen atom or a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl,

[0991] R 7 represents a hydrogen atom or a halogen atom or a radical selected from C1-C4-alkyl, C1-C4-alkoxy and hydroxy,

[0992] R 8 represents a group selected from methyl and ethyl,

[0993] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a radical selected from the group consisting of C1-C4-alkyl, C2-C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkoxy)-(C2-C4-alkyl)- and C3-C4-cycloalkyl,

[0994] or

[0995] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[0996] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, hydroxyl and oxo,

[0997] or

[0998] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[0999] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one or two times by C1-C4-alkyl,

[1000] R 11 represents a group selected from C1-C4-alkyl and C1-C4-haloalkyl,

[1001] R 12 represents hydrogen atoms,

[1002] R 13 represents phenyl,

[1003] R 14 represents a group selected from C1-C4-alkyl and phenyl,

[1004] R 15 represents a hydrogen atom or a C1-C4-alkyl group,

[1005] R 16 represents a hydrogen atom or a C1-C4-alkyl group,

[1006] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[1007] wherein the 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[1008] R 20 represents a (4- to 7-membered heterocycloalkyl)-(C1-C4-alkyl)- group,

[1009] and

[1010] n represents an integer selected from 1, 2 and 3.

[1011] According to a variant of the fifth embodiment of the first aspect, the present invention covers compounds of the above general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1012] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2,

[1013] R 2 represents a group selected from phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl,

[1014] wherein the 5- to 10-membered heteroaryl group is selected from the following groups:

[1015] pyrazolyl, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,3-thiazolyl, pyridyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, 1,3-benzoxazolyl, indazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl and 1,3-thiazolo[5,4-b]pyridinyl,

[1016] and

[1017] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1018] and

[1019] wherein phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or from the following groups:

[1020] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 ) 2, 4 to 7 membered heterocycloalkyl, phenyl and pyridyl,

[1021] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1022] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O)-C(C H3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2-C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O)-N(CH3)-,

[1023] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1024] and

[1025] wherein the C1-C4-alkoxy group is optionally substituted by a group selected from 4- to 7-membered heterocycloalkyl and phenyl,

[1026] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1027] and

[1028] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy,

[1029] R 3 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[1030] C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[1031] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1032] and

[1033] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[1034] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1035] and

[1036] wherein the C3-C4-cycloalkyl radical is optionally substituted once or twice by cyano,

[1037] and

[1038] wherein the C2-C4-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[1039] and

[1040] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice by a halogen atom or a radical selected from the group consisting of C1-C4-alkyl and C1-C4-haloalkyl,

[1041] R 4 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[1042] C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, -O-CH2-C(=O)OR 15 、-O-CH2-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, nitro, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 ),-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[1043] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1044] and

[1045] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[1046] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1047] and

[1048] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1049] and

[1050] wherein the C1-C4-alkoxy group is optionally substituted by an oxiran-2-yl group,

[1051] and

[1052] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1053] R 5 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[1054] C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 ), 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy,

[1055] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1056] R 6 represents a hydrogen atom or a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl,

[1057] R 7 represents a hydrogen atom or a halogen atom or a radical selected from the group consisting of C1-C4-alkyl, C1-C4-alkoxy and hydroxy,

[1058] R 8 represents a group selected from methyl and ethyl,

[1059] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a radical selected from the group consisting of C1-C4-alkyl, C2-C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkoxy)-(C2-C4-alkyl)- and C3-C4-cycloalkyl,

[1060] or

[1061] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[1062] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, hydroxyl and oxo,

[1063] or

[1064] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[1065] wherein the 4- to 7-membered heterocycloalkyl radical is optionally substituted one or two times by C1-C4-alkyl,

[1066] R 11 represents a group selected from C1-C4-alkyl and C1-C4-haloalkyl,

[1067] R12 represents a hydrogen atom,

[1068] R 13 represents phenyl,

[1069] R 14 represents a group selected from C1-C4-alkyl and phenyl,

[1070] R 15 represents a hydrogen atom or a C1-C4-alkyl group,

[1071] R 16 represents a hydrogen atom or a C1-C4-alkyl group,

[1072] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[1073] wherein the 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[1074] and

[1075] n represents an integer selected from 1, 2 and 3.

[1076] According to another variant of the fifth embodiment of the first aspect, the present invention covers compounds of the above-mentioned general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1077] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2,

[1078] R 2 represents a group selected from phenyl, 1-naphthyl and 5- to 10-membered heteroaryl,

[1079] wherein the 5- to 10-membered heteroaryl group is selected from the following groups:

[1080] pyrazolyl, 1,2,4-oxadiazole, 1,3-thiazolyl, pyridinyl, pyrazinyl, indolyl, benzofuranyl, 1,3-benzoxazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, and 1,3-thiazolo[5,4-b]pyridinyl, and

[1081] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1082] and

[1083] wherein phenyl, 1-naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or from the following groups:

[1084] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1085] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group selected from

[1086] R 3 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[1087] C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 ), 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[1088] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1089] and

[1090] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[1091] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1092] and

[1093] wherein the C3-C4-cycloalkyl radical is optionally substituted once or twice by cyano,

[1094] and

[1095] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice by a halogen atom,

[1096] R 4 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[1097] C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, -N(R 9 )(R 10 )、-N(R 16 )(R 17 ),-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[1098] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1099] and

[1100] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[1101] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1102] and

[1103] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1104] and

[1105] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1106] R 5 represents a hydrogen atom or a halogen atom, or a group selected from the following:

[1107] C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 ), 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy,

[1108] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1109] R 6 represents a hydrogen atom or a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl,

[1110] R 7 represents a hydrogen atom or a halogen atom or a group selected from C1-C4-alkyl and hydroxyl,

[1111] R 8 represents a group selected from methyl and ethyl,

[1112] R 9 and R 10 represents independently at each occurrence a hydrogen atom or a C1-C4-alkyl group,

[1113] or

[1114] R 9 and R 10 Together with the nitrogen to which they are attached, they represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group,

[1115] wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl, hydroxyl and oxo,

[1116] or

[1117] Two substituents, which are attached to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atoms to which they are attached represent a 4- to 7-membered heterocycloalkyl group,

[1118] wherein the 4- to 7-membered heterocycloalkyl radical is optionally substituted one or two times by C1-C4-alkyl,

[1119] R 11 represents a C1-C4-haloalkyl group,

[1120] R 12 represents a hydrogen atom,

[1121] R 13 represents phenyl,

[1122] R 14represents a group selected from C1-C4-alkyl and phenyl,

[1123] R 16 represents a hydrogen atom or a C1-C4-alkyl group,

[1124] R 17 represents a 4- to 7-membered heterocycloalkyl group,

[1125] wherein the 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl group,

[1126] and

[1127] n represents an integer selected from 1, 2 and 3.

[1128] According to a sixth embodiment of the first aspect, the present invention covers compounds of the above-mentioned general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1129] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2,

[1130] R 2 represents a group selected from phenyl, 1-naphthyl, 2-naphthyl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1H-1,2,3-triazol-4-yl, 2H-1,2,3-triazol-4-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzothiophene-2-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl , 1,3-benzoxazol-7-yl, 1H-indazol-5-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6-yl, quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl,

[1131] Wherein the group is optionally substituted one or two times, each substituent is independently selected from a fluorine, chlorine or bromine atom or a group selected from the following:

[1132] methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy, (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, oxetane -3-yl, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido, benzylsulfonylamino, [dimethyl(oxy)-λ 6 -sulfanyl]amino, phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl,

[1133] or

[1134] The two substituents of the phenyl group, when they are attached to adjacent ring atoms, are linked to each other in such a way that they together form a group selected from:

[1135] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O)-C(C H3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2-C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O)-N(CH3)-,

[1136] R 3represents a hydrogen atom or a fluorine, chlorine or bromine atom, or a group selected from the following: methyl, sec-butyl, (oxetan-3-yl)methyl, 3,3,3-trifluoroprop-1-en-2-yl, cyclopropyl, (trifluoromethyl)cyclopropyl, cyclobutyl, 2,2-dimethylcyclobutyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, ethoxy, propoxy, 2,2-difluoroethoxy, 2,2-difluoropropoxy, cyclo propylmethoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, carbamoyl, dimethylphosphoryl, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy and phenyl,

[1137] R 4 represents a hydrogen atom or a fluorine, chlorine or bromine atom or a group selected from the following: methyl, sec-butyl, (oxetan-3-yl)methyl, trifluoromethyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, propoxy, 2-methoxyethoxy, (1-hydroxycyclopropyl)methoxy, (1-cyanocyclopropyl)methoxy, (oxiran-2-yl)methoxy, carboxymethoxy, 2-tert-butoxy-2-oxo-ethoxy, 2-amino-2-oxo-ethoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, dimethylphosphoryl, cyano, nitro, hydroxy, (cyanomethyl)(methyl)amino, (2-Hydroxyethyl)amino, (2-hydroxyethyl)(methyl)amino, (2-methoxyethyl)amino, (2-methoxyethyl)(methyl)amino, cyclopropylamino, (oxetan-3-yl)amino, methyl(oxetan-3-yl)amino, methyl(oxolan-3-yl)amino, 3-hydroxyazetidin-1-yl, 2-oxopyrrolidin-1-yl, morpholinyl, 1,1-dioxidothiomorpholin-4-yl, 4-hydroxy-2-oxopyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 2,2-dimethyl-2λ 6 -diazathia-1,2-dien-1-yl, [dimethyl(oxy)-λ 6 -sulfanylidene]amino, methyl(tetrahydrofuran-3-yl)amino, tetrahydrofuran-3-ylmethoxy, (tetrahydrofuran-3-ylmethyl)amino, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy and phenyl,

[1138] R 5represents a hydrogen atom or a fluorine, chlorine or bromine atom or a group selected from the group consisting of methyl, cyclopropyl, methoxy, propoxy, cyclopropyloxy, methanesulfonyl, cyano, hydroxy, oxetan-3-yl and oxetan-3-yloxy,

[1139] R 6 represents a hydrogen atom or a group selected from methyl and hydroxymethyl,

[1140] R 7 represents a hydrogen atom or a fluorine atom or a group selected from methyl, ethyl, methoxy and hydroxy,

[1141] R 8 represents a group selected from methyl and ethyl,

[1142] and

[1143] n represents an integer selected from 1, 2 and 3.

[1144] According to a variant of the sixth embodiment of the first aspect, the present invention covers compounds of the above general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1145] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2,

[1146] R 2 represents a group selected from phenyl, 1-naphthyl, 2-naphthyl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzothiophene-2-yl, 1,3-benzoxazolyl-2-yl, 1,3-benzoxazolyl-5-yl, 1,3-benzoxazolyl-6-yl, 1,3-benzoxazolyl-7-yl, 1H -indazol-5-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6-yl, quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl,

[1147] Wherein the group is optionally substituted one or two times, each substituent is independently selected from a fluorine, chlorine or bromine atom or a group selected from the following:

[1148] methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy, (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, oxetane -3-yl, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido, benzylsulfonylamino, [dimethyl(oxy)-λ 6 -sulfanyl]amino, phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl,

[1149] or

[1150] The two substituents of the phenyl group, when they are attached to adjacent ring atoms, are linked to each other in such a way that they together form a group selected from:

[1151] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O)-C(C H3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2-C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O)-N(CH3)-,

[1152] R 3represents a hydrogen atom or a fluorine, chlorine or bromine atom, or a group selected from the following: methyl, sec-butyl, (oxetan-3-yl)methyl, 3,3,3-trifluoroprop-1-en-2-yl, cyclopropyl, (trifluoromethyl)cyclopropyl, cyclobutyl, 2,2-dimethylcyclobutyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, ethoxy, propoxy, 2,2-difluoroethoxy, 2,2-difluoropropoxy, cyclo propylmethoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, carbamoyl, dimethylphosphoryl, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy and phenyl,

[1153] R 4 represents a hydrogen atom or a fluorine, chlorine or bromine atom or a group selected from the following: methyl, sec-butyl, (oxetan-3-yl)methyl, trifluoromethyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, propoxy, 2-methoxyethoxy, (1-hydroxycyclopropyl)methoxy, (1-cyanocyclopropyl)methoxy, (oxiran-2-yl)methoxy, carboxymethoxy, 2-tert-butoxy-2-oxo-ethoxy, 2-amino-2-oxo-ethoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, dimethylphosphoryl, cyano, nitro, hydroxy, (cyanomethyl)(methyl)amino, (2-Hydroxyethyl)amino, (2-hydroxyethyl)(methyl)amino, (2-methoxyethyl)amino, (2-methoxyethyl)(methyl)amino, cyclopropylamino, (oxetan-3-yl)amino, methyl(oxetan-3-yl)amino, methyl(oxolan-3-yl)amino, 3-hydroxyazetidin-1-yl, 2-oxopyrrolidin-1-yl, morpholinyl, 1,1-dioxidothiomorpholin-4-yl, 4-hydroxy-2-oxopyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 2,2-dimethyl-2λ 6 -diazathia-1,2-dien-1-yl, [dimethyl(oxy)-λ 6 -sulfanylidene]amino, methyl(tetrahydrofuran-3-yl)amino, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy and phenyl,

[1154] R 5represents a hydrogen atom or a fluorine, chlorine or bromine atom or a group selected from the group consisting of methyl, cyclopropyl, methoxy, propoxy, cyclopropyloxy, methanesulfonyl, cyano, hydroxy, oxetan-3-yl and oxetan-3-yloxy,

[1155] R 6 represents a hydrogen atom or a group selected from methyl and hydroxymethyl,

[1156] R 7 represents a hydrogen atom or a fluorine atom or a group selected from methyl, ethyl, methoxy and hydroxy,

[1157] R 8 represents a group selected from methyl and ethyl,

[1158] and

[1159] n represents an integer selected from 1, 2 and 3.

[1160] According to another variant of the sixth embodiment of the first aspect, the present invention covers compounds of the above-mentioned general formula (I), and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1161] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2,

[1162] R 2 represents a group selected from phenyl, 1-naphthyl, 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1,3-benzooxazol-2-yl, 1,3-benzooxazol-5-yl, 1,3-benzooxazol-7-yl, 1H-benzimidazole-2-yl, -yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinolin-4-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl,

[1163] Wherein the group is optionally substituted one or two times, each substituent is independently selected from a fluorine, chlorine or bromine atom or a group selected from the following:

[1164] methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl, carbamoyl, trifluoroacetyl, benzamido, benzylsulfonamido, [dimethyl(oxy)-λ 6 -sulfanyl]amino and phenyl,

[1165] R 3 represents a hydrogen atom or a fluorine, chlorine or bromine atom, or a group selected from the group consisting of methyl, sec-butyl, (oxetan-3-yl)methyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, propoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy and phenyl,

[1166] R 4 represents a hydrogen atom or a fluorine, chlorine or bromine atom or a group selected from the following: methyl, sec-butyl, (oxetan-3-yl)methyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, propoxy, (1-hydroxycyclopropyl)methoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, cyano, 2-oxopyrrolidin-1-yl, morpholinyl, 1,1-dioxidothiomorpholin-4-yl, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 2,2-dimethyl-2λ 6 -diazathia-1,2-dien-1-yl, [dimethyl(oxy)-λ 6 -sulfanylidene]amino, methyl(tetrahydrofuran-3-yl)amino, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy and phenyl,

[1167] R 5represents a hydrogen atom or a fluorine, chlorine or bromine atom or a group selected from the group consisting of methyl, cyclopropyl, methoxy, propoxy, cyclopropyloxy, methanesulfonyl, cyano, hydroxy, oxetan-3-yl and oxetan-3-yloxy,

[1168] R 6 represents a hydrogen atom or a group selected from methyl and hydroxymethyl,

[1169] R 7 represents a hydrogen atom or a fluorine atom or a group selected from methyl, ethyl and hydroxyl groups,

[1170] R 8 represents a group selected from methyl and ethyl,

[1171] and

[1172] n represents an integer selected from 1, 2 and 3.

[1173] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1174] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 group.

[1175] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1176] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C2H5 and -C(=O)N(CH3)2.

[1177] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1178] R 1 represents a group selected from cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2.

[1179] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1180] R 1 Represents cyano.

[1181] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1182] R 1 represents a group selected from -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C2H5 and -C(=O)N(CH3)2.

[1183] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1184] R 1 represents a group selected from -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH3)2.

[1185] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1186] R 2 represents a group selected from the group consisting of phenyl, naphthyl and 5- to 10-membered heteroaryl,

[1187] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1188] and

[1189] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1190] C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1191] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1192] -(CH2)3-, -CH2-CH(OH)-CH2-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-CH(CH3)-O-, -CH2-O-CH2-, -O- (CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O-, -OC(CH3)2-O-, -O-(CH2)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-(C(CH2)3)-、-N(R 18 )-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O)-N(R 18 )-,

[1193] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1194] and

[1195] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1196] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1197] and

[1198] wherein the C1-C6-alkyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1199] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1200] and

[1201] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1202] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1203] and

[1204] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1205] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1206] and

[1207] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1208] and

[1209] wherein the C3-C6-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1210] and

[1211] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1212] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1213] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1214] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[1215] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1216] and

[1217] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1218] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C6-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14)2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1219] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1220] -(CH2)3-, -CH2-CH(OH)-CH2-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-CH(CH3)-O-, -CH2-O-CH2-, -O- (CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O-, -OC(CH3)2-O-, -O-(CH2)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-(C(CH2)3)-、-N(R 18 )-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O)-N(R 18 )-,

[1221] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1222] and

[1223] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1224] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1225] and

[1226] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1227] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1228] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1229] and

[1230] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1231] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1232] and

[1233] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1234] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1235] and

[1236] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1237] and

[1238] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1239] and

[1240] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1241] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1242] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1243] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[1244] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1245] and

[1246] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1247] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 ) 2, 4 to 7 membered heterocycloalkyl, phenyl and 5 or 6 membered heteroaryl,

[1248] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1249] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 19 )) m -、-N(R 18 )-C(=O)-(C(CH2)3)-、-N(R 18 )-(C(R 18 )(R 19 ))m -、-N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O)-N(R 18 )-,

[1250] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1251] and

[1252] wherein the C1-C4-alkoxy group is optionally substituted by a group selected from the group consisting of 4- to 7-membered heterocycloalkyl and phenyl,

[1253] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1254] and

[1255] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1256] C1-C2-Alkyl, C1-C2-haloalkyl and C1-C2-alkoxy.

[1257] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1258] R 2 represents a group selected from phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl,

[1259] wherein the 5- to 10-membered heteroaryl group is selected from the following groups:

[1260] pyrazolyl, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1,3-thiazolyl, pyridyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, 1,3-benzoxazolyl, indazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolyl, isoquinolyl, quinoxalinyl and 1,3-thiazolo[5,4-b]pyridinyl,

[1261] and

[1262] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1263] and

[1264] wherein phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or from the following groups:

[1265] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 ) 2, 4 to 7 membered heterocycloalkyl, phenyl and pyridyl,

[1266] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1267] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O)-C(C H3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2-C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O)-N(CH3)-,

[1268] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1269] and

[1270] wherein the C1-C4-alkoxy group is optionally substituted by a group selected from 4- to 7-membered heterocycloalkyl and phenyl,

[1271] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1272] and

[1273] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy.

[1274] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1275] R 2 represents a group selected from 5- to 10-membered heteroaryl,

[1276] wherein the 5- to 10-membered heteroaryl group is selected from the following groups:

[1277] pyrazolyl, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1,3-thiazolyl, pyridyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, 1,3-benzoxazolyl, indazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, and 1,3-thiazolo[5,4-b]pyridinyl, and

[1278] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1279] and

[1280] wherein the 5- to 10-membered heteroaryl group is optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or from the following groups:

[1281] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 ) 2, 4 to 7 membered heterocycloalkyl, phenyl and pyridyl,

[1282] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1283] and

[1284] wherein the C1-C4-alkoxy group is optionally substituted by a group selected from 4- to 7-membered heterocycloalkyl and phenyl,

[1285] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1286] and

[1287] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy.

[1288] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1289] R 2 represents a group selected from phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl,

[1290] wherein the 5- to 10-membered heteroaryl group is selected from the following groups:

[1291] pyrazolyl, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,3-thiazolyl, pyridyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, 1,3-benzoxazolyl, indazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl and 1,3-thiazolo[5,4-b]pyridinyl,

[1292] and

[1293] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1294] and

[1295] wherein phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or from the following groups:

[1296] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 ) 2, 4 to 7 membered heterocycloalkyl, phenyl and pyridyl,

[1297] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1298] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O)-C(C H3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2-C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O)-N(CH3)-,

[1299] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1300] and

[1301] wherein the C1-C4-alkoxy group is optionally substituted by a group selected from 4- to 7-membered heterocycloalkyl and phenyl,

[1302] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1303] and

[1304] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy.

[1305] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1306] R 2 represents a group selected from phenyl, 1-naphthyl, 2-naphthyl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1H-1,2,3-triazol-4-yl, 2H-1,2,3-triazol-4-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzothiophene-2-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl , 1,3-benzoxazol-7-yl, 1H-indazol-5-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6-yl, quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl,

[1307] Wherein the group is optionally substituted one or two times, each substituent is independently selected from a fluorine, chlorine or bromine atom or a group selected from the following:

[1308] methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy, (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, oxetane -3-yl, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido, benzylsulfonylamino, [dimethyl(oxy)-λ 6-sulfanyl]amino, phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl,

[1309] or

[1310] The two substituents of the phenyl group, when they are attached to adjacent ring atoms, are linked to each other in such a way that they together form a group selected from:

[1311] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O)-C(C H3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2-C(CH3)2-, -N(CH3)-C(=O)-O-, and -N(CH3)-C(=O)-N(CH3)-.

[1312] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1313] R 2 The representative is selected from 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1H-1,2,3-triazol-4-yl, 2H-1,2,3-triazol-4-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzothiophen-2-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzo oxazol-7-yl, 1H-indazol-5-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6-yl, quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl,

[1314] Wherein the group is optionally substituted one or two times, each substituent is independently selected from a fluorine, chlorine or bromine atom or a group selected from the following:

[1315] methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy, (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, oxetane -3-yl, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido, benzylsulfonylamino, [dimethyl(oxy)-λ 6 -sulfanyl]amino, phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl,

[1316] or

[1317] The two substituents of the phenyl group, when they are attached to adjacent ring atoms, are linked to each other in such a way that they together form a group selected from:

[1318] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O)-C(C H3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2-C(CH3)2-, -N(CH3)-C(=O)-O-, and -N(CH3)-C(=O)-N(CH3)-.

[1319] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1320] R 2represents a group selected from phenyl, 1-naphthyl, 2-naphthyl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzothiophene-2-yl, 1,3-benzoxazolyl-2-yl, 1,3-benzoxazolyl-5-yl, 1,3-benzoxazolyl-6-yl, 1,3-benzoxazolyl-7-yl, 1H -indazol-5-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6-yl, quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl,

[1321] Wherein the group is optionally substituted one or two times, each substituent is independently selected from a fluorine, chlorine or bromine atom or a group selected from the following:

[1322] methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy, (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, oxetane -3-yl, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido, benzylsulfonylamino, [dimethyl(oxy)-λ 6 -sulfanyl]amino, phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl,

[1323] or

[1324] The two substituents of the phenyl group, when they are attached to adjacent ring atoms, are linked to each other in such a way that they together form a group selected from:

[1325] -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O)-C(C H3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2-C(CH3)2-, -N(CH3)-C(=O)-O-, and -N(CH3)-C(=O)-N(CH3)-.

[1326] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1327] R 2 represents a group selected from the group consisting of phenyl, naphthyl and 5- to 10-membered heteroaryl,

[1328] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1329] and

[1330] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1331] C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14)2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1332] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1333] -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O-(CH2)2-O-,

[1334] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1335] and

[1336] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1337] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1338] and

[1339] wherein the C1-C6-alkyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1340] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1341] and

[1342] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1343] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1344] and

[1345] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1346] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1347] and

[1348] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1349] and

[1350] wherein the C3-C6-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1351] and

[1352] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1353] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1354] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1355] R 2 represents a group selected from the group consisting of phenyl, naphthyl and 5- to 10-membered heteroaryl,

[1356] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1357] and

[1358] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1359] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C6-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1360] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1361] -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O-(CH2)2-O-,

[1362] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1363] and

[1364] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1365] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R9 )(R 10 ) and oxo,

[1366] and

[1367] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1368] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1369] and

[1370] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1371] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1372] and

[1373] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1374] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1375] and

[1376] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1377] and

[1378] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1379] and

[1380] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1381] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R9 )(R 10 ).

[1382] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1383] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[1384] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1385] and

[1386] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1387] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1388] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group,

[1389] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from the following:

[1390] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1391] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1392] R 2 represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl,

[1393] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1394] and

[1395] wherein phenyl, naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1396] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1397] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group.

[1398] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1399] R 2 represents a group selected from phenyl, 1-naphthyl and 5- to 10-membered heteroaryl,

[1400] wherein the 5- to 10-membered heteroaryl group is selected from the following groups:

[1401] pyrazolyl, 1,2,4-oxadiazolyl, 1,3-thiazolyl, pyridinyl, pyrazinyl, indolyl, benzofuranyl, 1,3-benzoxazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, and 1,3-thiazolo[5,4-b]pyridinyl, and

[1402] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1403] and

[1404] wherein phenyl, 1-naphthyl and 5- to 10-membered heteroaryl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1405] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1406] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group.

[1407] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1408] R 2represents a group selected from the group consisting of phenyl, 1-naphthyl, 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1,3-benzooxazol-2-yl, 1,3-benzooxazol-5-yl, 1,3-benzooxazol-7-yl, 1H-benzimidazole oxazol-2-yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinolin-4-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl,

[1409] Wherein the group is optionally substituted once or twice, each substituent is independently selected from a fluorine, chlorine or bromine atom or a group selected from the following:

[1410] methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl, carbamoyl, trifluoroacetyl, benzamido, benzylsulfonamido, [dimethyl(oxy)-λ 6 -sulfanyl]amino and phenyl.

[1411] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1412] R 2 represents a 5- to 10-membered heteroaryl group,

[1413] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1414] and

[1415] wherein the 5- to 10-membered heteroaryl group is optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1416] C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1417] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1418] and

[1419] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1420] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1421] and

[1422] wherein the C1-C6-alkyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1423] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1424] and

[1425] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1426] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1427] and

[1428] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1429] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1430] and

[1431] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1432] and

[1433] wherein the C3-C6-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1434] and

[1435] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1436] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1437] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1438] R 2 represents a 5- to 10-membered heteroaryl group,

[1439] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1440] and

[1441] wherein the 5- to 10-membered heteroaryl group is optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1442] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C6-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1443] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1444] and

[1445] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1446] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1447] and

[1448] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1449] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1450] and

[1451] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1452] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1453] and

[1454] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1455] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1456] and

[1457] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1458] and

[1459] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1460] and

[1461] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1462] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1463] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1464] R 2 represents a 5- to 10-membered heteroaryl group,

[1465] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1466] and

[1467] wherein the 5- to 10-membered heteroaryl group is optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1468] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1469] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group,

[1470] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from the following:

[1471] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1472] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1473] R 2 represents a 5- to 10-membered heteroaryl group,

[1474] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1475] and

[1476] wherein the 5- to 10-membered heteroaryl group is optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1477] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1478] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group.

[1479] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1480] R 2 represents a 5- to 10-membered heteroaryl group,

[1481] wherein the 5- to 10-membered heteroaryl group is selected from the following groups:

[1482] pyrazolyl, 1,2,4-oxadiazolyl, 1,3-thiazolyl, pyridinyl, pyrazinyl, indolyl, benzofuranyl, 1,3-benzoxazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, and 1,3-thiazolo[5,4-b]pyridinyl, and

[1483] wherein the 5- to 10-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5- to 10-membered heteroaryl group,

[1484] and

[1485] wherein the 5- to 10-membered heteroaryl group is optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1486] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1487] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group.

[1488] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1489] R 2 represents a group selected from the group consisting of 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1,3-benzooxazol-2-yl, 1,3-benzooxazol-5-yl, 1,3-benzooxazol-7-yl, 1H-benzimidazole-2-yl yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinolin-4-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl,

[1490] Wherein the group is optionally substituted once or twice, each substituent is independently selected from a fluorine, chlorine or bromine atom or a group selected from the following:

[1491] methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl, carbamoyl, trifluoroacetyl, benzamido, benzylsulfonamido, [dimethyl(oxy)-λ 6 -sulfanyl]amino and phenyl.

[1492] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1493] R 2 represents a group selected from phenyl and naphthyl,

[1494] wherein phenyl and naphthyl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1495] C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1496] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1497] -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O-(CH2)2-O-,

[1498] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1499] and

[1500] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1501] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1502] and

[1503] wherein the C1-C6-alkyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1504] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1505] and

[1506] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1507] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1508] and

[1509] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1510] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1511] and

[1512] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1513] and

[1514] wherein the C3-C6-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1515] and

[1516] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1517] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1518] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1519] R 2 represents a group selected from phenyl and naphthyl,

[1520] wherein phenyl and naphthyl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1521] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C6-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 、-P(=O)(R14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1522] or two substituents of said phenyl, when they are attached to adjacent ring atoms, are optionally linked to each other in such a way that they together form a group selected from:

[1523] -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O-, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O-(CH2)2-O-,

[1524] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1525] and

[1526] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1527] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1528] and

[1529] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1530] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1531] and

[1532] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1533] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1534] and

[1535] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1536] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1537] and

[1538] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1539] and

[1540] wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical,

[1541] and

[1542] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1543] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1544] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1545] R 2represents a group selected from phenyl and naphthyl,

[1546] wherein phenyl and naphthyl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1547] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1548] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group,

[1549] wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from the following:

[1550] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1551] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1552] R 2 represents a group selected from phenyl and naphthyl,

[1553] wherein phenyl and naphthyl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1554] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1555] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group.

[1556] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1557] R 2 represents a group selected from phenyl and 1-naphthyl,

[1558] wherein phenyl and 1-naphthyl are optionally substituted one, two, three or four times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1559] C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 、-P(=O)(R 14 )2, cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=O)(R 14 )2 and phenyl,

[1560] wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group.

[1561] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1562] R 2represents a group selected from phenyl, 1-naphthyl,

[1563] wherein phenyl and naphthyl are optionally substituted once or twice, each substituent being independently selected from a fluorine, chlorine or bromine atom or a group selected from the following:

[1564] methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4.5]dec-2-yl, carbamoyl, trifluoroacetyl, benzamido, benzylsulfonamido, [dimethyl(oxy)-λ 6 -sulfanyl]amino and phenyl.

[1565] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1566] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1567] C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1568] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1569] and

[1570] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1571] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1572] and

[1573] wherein the C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1574] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1575] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1576] and

[1577] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1578] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1579] and

[1580] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1581] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R9 )(R 10 ),

[1582] and

[1583] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1584] and

[1585] wherein the C2-C6-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[1586] and

[1587] wherein the C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl and C1-C4-haloalkyl,

[1588] and

[1589] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1590] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1591] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1592] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1593] C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2 alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1594] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1595] and

[1596] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1597] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1598] and

[1599] wherein the C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1600] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1601] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1602] and

[1603] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1604] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1605] and

[1606] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1607] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1608] and

[1609] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1610] and

[1611] wherein the C2-C4-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[1612] and

[1613] wherein the C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl and C1-C4-haloalkyl,

[1614] and

[1615] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1616] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1617] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1618] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1619] C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C5-cycloalkoxy, -S(=O)2R14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[1620] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1621] and

[1622] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1623] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1624] and

[1625] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1626] C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl,

[1627] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1628] and

[1629] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1630] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1631] and

[1632] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1633] and

[1634] wherein the C2-C4-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[1635] and

[1636] Wherein the C3-C5-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl and C1-C4-haloalkyl.

[1637] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1638] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1639] C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[1640] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1641] and

[1642] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1643] C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl,

[1644] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1645] and

[1646] wherein the C3-C4-cycloalkyl radical is optionally substituted once or twice by cyano,

[1647] and

[1648] wherein the C2-C4-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[1649] and

[1650] Wherein the C3-C5-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl and C1-C4-haloalkyl.

[1651] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1652] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1653] C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C5-cycloalkoxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[1654] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1655] and

[1656] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1657] C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl,

[1658] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1659] and

[1660] wherein the C3-C4-cycloalkyl radical is optionally substituted once or twice by cyano,

[1661] and

[1662] wherein the C2-C4-alkenyl group is optionally substituted by a C1-C4-haloalkyl group,

[1663] and

[1664] Wherein the C3-C5-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C4-alkyl and C1-C4-haloalkyl.

[1665] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1666] R 3 represents a hydrogen atom or a fluorine, chlorine or bromine atom, or a group selected from the following: methyl, sec-butyl, (oxetan-3-yl)methyl, 3,3,3-trifluoroprop-1-en-2-yl, cyclopropyl, (trifluoromethyl)cyclopropyl, cyclobutyl, 2,2-dimethylcyclobutyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, ethoxy, propoxy, 2,2-difluoroethoxy, 2,2-difluoropropoxy, cyclo propylmethoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, carbamoyl, dimethylphosphoryl, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy and phenyl.

[1667] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1668] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1669] C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R 14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1670] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1671] and

[1672] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1673] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1674] and

[1675] wherein the C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1676] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1677] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1678] and

[1679] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1680] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R10 ) and oxo,

[1681] and

[1682] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1683] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1684] and

[1685] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1686] and

[1687] wherein the C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[1688] and

[1689] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1690] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1691] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1692] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1693] C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2 alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, -SR 14 、-S(=O)R14 、-S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1694] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1695] and

[1696] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1697] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1698] and

[1699] wherein the C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1700] C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl,

[1701] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1702] and

[1703] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1704] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1705] and

[1706] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1707] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1708] and

[1709] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1710] and

[1711] wherein the C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[1712] and

[1713] wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1714] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1715] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1716] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1717] C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R10 ),-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[1718] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1719] and

[1720] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1721] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1722] and

[1723] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1724] C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl,

[1725] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1726] and

[1727] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1728] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1729] and

[1730] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1731] and

[1732] The C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical.

[1733] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1734] R 3 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1735] C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxyl, -N(R 9 )(R 10 ), 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy and phenyl,

[1736] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1737] and

[1738] wherein the C1-C6-alkyl and C1-C4-alkoxy groups are optionally substituted by groups selected from the group consisting of:

[1739] C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl,

[1740] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1741] and

[1742] wherein the C3-C4-cycloalkyl radical is optionally substituted once or twice by cyano,

[1743] and

[1744] wherein the C3-C5-cycloalkyl group is optionally substituted once or twice by halogen atoms.

[1745] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1746] R 3represents a hydrogen atom or a fluorine, chlorine or bromine atom, or a group selected from the following: methyl, sec-butyl, (oxetan-3-yl)methyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, propoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy and phenyl.

[1747] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1748] R 4 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1749] C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl)-, C1-C6-alkoxy, (C1-C2-alkoxy)-(C1-C6-alkoxy)-, C1-C4-haloalkoxy, -O-(C1-C4-alkyl)-C(=O)OR 15 、-O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C6-cycloalkyloxy, -S(=O)R 14 、-S(=O)2R 14 , cyano, nitro, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-N(R 16 )(R 20 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14)2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1750] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1751] and

[1752] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1753] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1754] and

[1755] wherein the C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[1756] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1757] and

[1758] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1759] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1760] and

[1761] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1762] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1763] and

[1764] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1765] and

[1766] wherein the C1-C6-alkoxy group is optionally substituted by an oxiran-2-yl group,

[1767] and

[1768] wherein the C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[1769] and

[1770] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1771] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1772] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1773] R 4 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1774] C1-C6-alkyl, C1-C6-haloalkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1-C5-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, -O-(C1-C4-alkyl)-C(=O)OR 15 、-O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, -S(=O)R 14 、-S(=O)2R 14 , cyano, nitro, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R17 )、-N(R 16 )(R 20 )、-C(=O)N(R 9 )(R 10 ),-C(=O)R 11 、-N(R 12 )C(=O)R 13 、-N(R 12 )S(=O)2R 14 、-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 )2、-P(=O)(R 14 )2, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl,

[1775] wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups,

[1776] and

[1777] wherein the 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, and (4- to 7-membered heterocycloalkyl)oxy groups are optionally substituted one, two, or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1778] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo,

[1779] and

[1780] wherein the C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl groups,

[1781] wherein said 4- to 7-membered heterocycloalkyl group is attached to the remainder of the molecule via a carbon atom of said 4- to 7-membered heterocycloalkyl group,

[1782] and

[1783] wherein the 4- to 7-membered heterocycloalkyl group is optionally substituted one, two or three times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1784] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R10 ) and oxo,

[1785] and

[1786] wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1787] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ),

[1788] and

[1789] wherein the C3-C4-cycloalkyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from a cyano group and a hydroxyl group,

[1790] and

[1791] wherein the C1-C4-alkoxy group is optionally substituted by an oxiran-2-yl group,

[1792] and

[1793] wherein the C3-C5-cycloalkyl and C4-C6-cycloalkenyl groups are optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl group,

[1794] and

[1795] wherein the phenyl group and the 5- or 6-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from the following:

[1796] C1-C2-alkyl, C1-C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ).

[1797] In another embodiment of the first aspect, the present invention encompasses compounds of formula (I) above, and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof, wherein:

[1798] R 4 represents a hydrogen atom or a halogen atom or a group selected from the following:

[1799] C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, -O-(C1-C4-alkyl)-C(=O)OR 15 、-O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, nitro, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-N(R 16 )(R 20 ),-N=S(=NH)(R 14 )2、-N=S(=O)(R 14 ...

Claims

1. An oral preparation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a 5-membered heteroaryl group selected from the group consisting of pyrazolyl, 1,3,4-oxadiazole, 1H-1,2,3-triazolyl and 2H-1,2,3-triazolyl, wherein the 5-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5-membered heteroaryl group, and wherein the 5-membered heteroaryl is substituted once by a radical selected from phenyl and pyridyl, wherein the phenyl is optionally substituted once by C1-C2-alkyl, R 3 represents a halogen atom or a C1-C6-alkyl group, R 4 represents a group selected from the following: hydroxyl, -N(R 9 )(R 10 ) and (4- to 7-membered heterocycloalkyl)oxy, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom, R 8 Represents methyl, R 9 and R 10 represents independently at each occurrence a hydrogen atom or a C2-C4-hydroxyalkyl group, and n represents an integer of 2.

2. The oral preparation according to claim 1, wherein: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a group selected from 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1,3,4-oxadiazol-2-yl, 1H-1,2,3-triazol-4-yl and 2H-1,2,3-triazol-4-yl, wherein the group is substituted once by a group selected from 2-methylphenyl and pyridin-3-yl, R 3 represents a bromine atom or a methyl group, R 4 represents a group selected from the group consisting of hydroxy, (2-hydroxyethyl)amino and (tetrahydrofuran-3-yl)oxy, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom, R 8 Represents methyl, and n represents an integer of 2.

3. An oral preparation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents 1,2,4-oxadiazole, wherein the 1,2,4-oxadiazole is attached to the remainder of the molecule via a carbon atom of said 1,2,4-oxadiazole, and Where 1,2,4-oxadiazole is substituted once by a phenyl group, wherein the phenyl group is optionally substituted once by C1-C2-alkyl, R 3 represents a halogen atom or a cyano group, R 4 represents a group selected from the group consisting of: C1-C4-alkoxy, hydroxy, -N(R 9 )(R 10 ) and (4- to 7-membered heterocycloalkyl)oxy, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom, R 8 Represents methyl, R 9 and R 10 represents independently at each occurrence a hydrogen atom or a C2-C4-hydroxyalkyl group, and n represents an integer of 2.

4. The oral preparation according to claim 3, wherein: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents 1,2,4-oxadiazol-5-yl, wherein the radical is substituted once by 2-methylphenyl, R 3 represents a bromine atom or a cyano group, R 4 represents a group selected from the group consisting of methoxy, hydroxy, (2-hydroxyethyl)amino and (tetrahydrofuran-3-yl)oxy, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom, R 8 Represents methyl, and n represents an integer of 2.

5. An oral preparation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents 1,3-benzoxazolyl, wherein the 1,3-benzoxazolyl group is attached to the remainder of the molecule via a carbon atom of said 1,3-benzoxazolyl group, and wherein the 1,3-benzoxazolyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a methyl group, R 3 represents a halogen atom or a group selected from the group consisting of C1-C6-alkyl, C1-C4-alkoxy and cyano, R 4 represents a fluorine atom or a group selected from the following: C1-C4-alkoxy, hydroxyl, -N(R 9 )(R 10 )、-N(R 16 )(R 17 )、-N(R 16 )(R 20 ) and (4- to 7-membered heterocycloalkyl)oxy, wherein the C1-C4-alkoxy group is optionally substituted by a 4- to 7-membered heterocycloalkyl group, wherein the 4- to 7-membered heterocycloalkyl is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom or a halogen atom or a C1-C4-alkyl group, R 8 Represents methyl, R 9 and R 10 represents independently at each occurrence a hydrogen atom or a radical selected from C1-C4-alkyl, C2-C4-hydroxyalkyl and (C1-C4-alkoxy)-(C2-C4-alkyl)-, or R 9 and R 10 Together with the nitrogen to which they are attached, represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group, wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl is optionally substituted once with a hydroxyl group, R 16 represents a hydrogen atom or a C1-C4-alkyl group, R 17 represents a 4- to 7-membered heterocycloalkyl group, wherein the 4- to 7-membered heterocycloalkyl is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl, R 20 represents a (4- to 7-membered heterocycloalkyl)-(C1-C4-alkyl)-group, and n represents an integer of 2.

6. The oral preparation according to claim 5, wherein: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a 1,3-benzoxazol-2-yl group, wherein the group is substituted once by a methyl group, R 3 represents a chlorine or bromine atom, or a group selected from the group consisting of a methyl group, a methoxy group, an ethoxy group and a cyano group, R 4 represents a fluorine atom or a group selected from the group consisting of methoxy, hydroxy, (2-hydroxyethyl)amino, (2-hydroxyethyl)(methyl)amino, (2-methoxyethyl)amino, (oxetan-3-yl)amino, 3-hydroxyazetidin-1-yl, tetrahydrofuran-3-ylmethoxy, (tetrahydrofuran-3-ylmethyl)amino and (tetrahydrofuran-3-yl)oxy, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom or a fluorine atom or a methyl group, R 8 Represents methyl, and n represents an integer of 2.

7. An oral preparation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a group selected from phenyl and 9-membered heteroaryl, The 9-membered heteroaryl group is selected from the following groups: 1,3-benzoxazolyl and 1,3-benzothiazolyl, and wherein the 9-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 9-membered heteroaryl group, and wherein the phenyl group and the 9-membered heteroaryl group are optionally substituted one or two times, each substituent being independently selected from a halogen atom or from the following groups: C1-C6-alkyl, C1-C4-alkoxy and C1-C4-haloalkoxy, R 3 represents a hydrogen atom, R 4 represents a halogen atom, or a group selected from the following: Methyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl)-, methoxy, (C1-C2-alkoxy)-(C1-C4-alkoxy)-, -O-CH2-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, hydroxyl, -N(R 9 )(R 10 ), methyl(oxetan-3-yl)amino, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (oxetan-3-yl)oxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy and phenyl, wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups, and wherein the methyl and methoxy groups are optionally substituted by groups selected from C3-C4-cycloalkyl and 4- to 7-membered heterocycloalkyl, wherein the 4- to 7-membered heterocycloalkyl is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl, and wherein the C3-C4-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a radical selected from a cyano group and a hydroxyl group, and wherein the methoxy group is optionally substituted by an oxiran-2-yl group, and wherein the C3-C5-cycloalkyl radical is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a C1-C4-alkyl radical, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom or a halogen atom or a C1-C4-alkyl group, R 8 Represents methyl, R 9 and R 10 represents independently at each occurrence a hydrogen atom or a radical selected from C1-C4-alkyl, C2-C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkoxy)-(C2-C4-alkyl)- and C3-C4-cycloalkyl, or R 9 and R 10 Together with the nitrogen to which they are attached, they represent a morpholinyl group, and n represents an integer selected from 2 and 3.

8. The oral preparation according to claim 7, wherein: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a group selected from phenyl, 1,3-benzooxazol-2-yl and 1,3-benzothiazol-2-yl, Wherein the group is optionally substituted one or two times, each substituent is independently selected from a fluorine or chlorine atom or a group selected from the following: methyl, isopropyl, methoxy and trifluoromethoxy, R 3 represents a hydrogen atom, R 4 represents a fluorine, chlorine or bromine atom or a group selected from the group consisting of methyl, (oxetan-3-yl)methyl, trifluoromethyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, 2-methoxyethoxy, (1-hydroxycyclopropyl)methoxy, (1-cyanocyclopropyl)methoxy, (oxiran-2-yl)methoxy, 2-amino-2-oxo-ethoxy, cyclopropyloxy, cyclobutyloxy, hydroxy, (cyanomethyl)(methyl)amino, (2-hydroxyethyl)amino, (2-hydroxyethyl)(methyl)amino, cyclopropylamino, methyl(oxetan-3-yl)amino, morpholinyl, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy and phenyl, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom or a fluorine atom or a group selected from a methyl group and an ethyl group, R 8 Represents methyl, and n represents an integer selected from 2 and 3.

9. An oral preparation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a 5-membered heteroaryl group selected from the group consisting of pyrazolyl, 1,2,4-oxadiazole and 1,3-thiazolyl, wherein the 5-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 5-membered heteroaryl group, and wherein the 5-membered heteroaryl is substituted once by a phenyl group, wherein the phenyl group is optionally substituted once or twice, each substituent being independently selected from a halogen atom or a group selected from C1-C2-alkyl and C1-C2-alkoxy, R 3 represents a hydrogen atom, R 4 represents a hydrogen atom, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom, R 8 Represents methyl, and n represents an integer of 2.

10. The oral preparation according to claim 9, wherein: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a group selected from 1H-pyrazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,3-thiazol-2-yl, wherein the group is substituted once by a group selected from: 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl and 4-methoxyphenyl, R 3 represents a hydrogen atom, R 4 represents a hydrogen atom, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom, R 8 Represents methyl, and n represents 2.

11. An oral preparation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 A group representing a 9-membered heteroaryl group selected from the following groups: indolyl, benzothienyl, benzofuranyl, 1,3-benzooxazol-2-yl, 1,3-benzooxazol-6-yl, 1,3-benzooxazol-7-yl, indazolyl, 1,3-benzothiazolyl and 1,3-thiazolo[5,4-b]pyridinyl, wherein the 9-membered heteroaryl group is attached to the remainder of the molecule via a carbon atom of said 9-membered heteroaryl group, and The 9-membered heteroaryl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or from the following groups: C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, hydroxy, -C(=O)R 11 , 4 to 7 membered heterocycloalkyl, wherein the 4- to 7-membered heterocycloalkyl is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl, and wherein the C1-C4-alkoxy group is optionally substituted by a 4- to 7-membered heterocycloalkyl group, wherein the 4- to 7-membered heterocycloalkyl is attached to the remainder of the molecule via a carbon atom of the 4- to 7-membered heterocycloalkyl, R 3 represents a hydrogen atom, R 4 represents a hydrogen atom, R 5 represents a hydrogen atom, or a group selected from the following: methyl, methoxy, cyclopropyloxy, methanesulfonyl, oxetan-3-yl and oxetan-3-yloxy, R 6 represents a hydrogen atom or a C1-C4-alkyl group, R 7 represents a hydrogen atom or a radical selected from C1-C4-alkyl and C1-C4-alkoxy, R 8 Represents methyl, R 11 represents a C1-C4-haloalkyl group, and n represents an integer selected from 2 and 3.

12. The oral formulation according to claim 11, wherein: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a group selected from 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzothiophen-2-yl, 1,3-benzooxazol-2-yl, 1,3-benzooxazol-6-yl, 1,3-benzooxazol-7-yl, 1H-indazol-5-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzothiazol-7-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl, Wherein the group is optionally substituted one or two times, each substituent is independently selected from a fluorine, chlorine or bromine atom or a group selected from the following: methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, methoxymethyl, 2-methoxyethyl, trifluoromethoxy, (oxolan-2-yl)methoxy, (tetrahydrofuran-2-yl)methoxy, oxetan-3-yl and trifluoroacetyl, R 3 represents a hydrogen atom, R 4 represents a hydrogen atom, R 5 represents a hydrogen atom or a group selected from the group consisting of methyl, methoxy, cyclopropyloxy, mesyl, oxetan-3-yl and oxetan-3-yloxy, R 6 represents a hydrogen atom or a methyl group, R 7 represents a hydrogen atom or a group selected from methyl, ethyl and methoxy, R 8 Represents methyl, and n represents an integer selected from 2 and 3.

13. An oral preparation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents phenyl, Wherein the phenyl group is optionally substituted one or two times, each substituent being independently selected from a fluorine atom, a chlorine atom or selected from the following groups: C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, hydroxy, -N(R 9 )(R 10 ), -C(=O)R 11 、-N(R 12 )C(=O)R 13 , 4- to 7-membered heterocycloalkyl and phenyl, Or two substituents of the phenyl group, when they are attached to adjacent ring atoms, are optionally attached to each other in such a way that they together form a group selected from: -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, and -NH-CH2-C(CH3)2-, wherein the C1-C4-alkoxy group is optionally substituted by a phenyl group, R 3 represents a hydrogen atom, R 4 represents a hydrogen atom, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom or a C1-C4-alkyl group, R 7 represents a hydrogen atom or a C1-C4-alkyl group, R 8 Represents methyl, R 9 and R 10 represents independently at each occurrence a hydrogen atom or a C1-C4-alkyl group, or R 9 and R 10 Together with the nitrogen to which they are attached, represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group, R 11 represents a C1-C4-alkyl group, R 12 represents a hydrogen atom, R 13 represents phenyl, and n represents an integer selected from 2 and 3.

14. The oral formulation according to claim 13, wherein: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents phenyl, Wherein the group is optionally substituted once or twice, each substituent is independently selected from a fluorine atom, a chlorine atom or a group selected from the following: methyl, isopropyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (prop-2-yl)oxy, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, hydroxy, dimethylamino, morpholin-4-yl, acetyl, benzamido and phenyl, or The two substituents of the phenyl group, when they are attached to adjacent ring atoms, are linked to each other in such a way that they together form a group selected from: -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC(CH3)2-O-, and -NH-CH2-C(CH3)2-, R 3 represents a hydrogen atom, R 4 represents a hydrogen atom, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom or a methyl group, R 7 represents a hydrogen atom or a group selected from methyl and ethyl, R 8 Represents methyl, and n represents an integer selected from 2 and 3.

15. An oral preparation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a group selected from phenyl, 1,3-benzooxazol-2-yl and 1,3-benzothiazol-2-yl, wherein the group is optionally substituted one or two times, each substituent being independently selected from a chlorine atom or a group selected from the group consisting of methyl, isopropyl and methoxy, R 3 represents a fluorine or bromine atom, or a group selected from the group consisting of a methyl group, a methoxymethyl group, a methoxy group, a cyano group and a hydroxyl group, R 4 represents a hydrogen atom, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom or a methyl group, R 8 Represents methyl, and n represents an integer selected from 2 and 3.

16. The oral formulation of claim 15, wherein the compound is 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, or a salt thereof, or a mixture thereof.

17. The oral formulation of claim 15, wherein the compound is 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, or a pharmaceutically acceptable salt thereof.

18. The oral formulation of claim 15, wherein the compound is 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide.

19. An oral formulation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents a group selected from 1,2,4-oxadiazol-5-yl and 1,3,4-oxadiazol-2-yl, wherein the group is substituted once by a group selected from the group consisting of phenyl, 2-methylphenyl, 3-methylphenyl and 3-trifluoromethylphenyl, R 3 represents a bromine atom, R 4 represents a hydrogen atom, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom, R 8 Represents methyl, and n represents an integer of 2.

20. An oral formulation comprising a compound of general formula (I), or a salt thereof, or a mixture thereof: in: R 1 represents a group selected from cyano and -C(=O)NH2, R 2 represents 1,2,4-oxadiazol-5-yl, wherein the group is substituted once by a group selected from the group consisting of phenyl, 2-methylphenyl and 3-methylphenyl, R 3 represents methoxy, R 4 represents a hydrogen atom, R 5 represents a hydrogen atom, R 6 represents a hydrogen atom, R 7 represents a hydrogen atom, R 8 Represents methyl, and n represents an integer of 2.

21. An oral formulation comprising a compound, or a salt thereof, or a mixture thereof, wherein the compound is selected from: 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(7-fluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-fluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-fluoro-1,3-benzooxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzooxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-bromo-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-fluoro-1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-bromo-1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(7-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)-4-fluoropiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(4-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro-1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro[1,3]thiazolo[5,4-b]pyridin-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-methyl-4-[6-(trifluoromethoxy)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzooxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5,6-difluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-tert-butyl-1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-fluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1-methyl-4-{4-methyl-4-[6-(trifluoromethoxy)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-4-[4-(5-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1-methyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzooxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-4-[4-(5,6-difluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-4-[4-(6-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1-methyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(2,2,2-trifluoroethoxy)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-(4-{4-[(propan-2-yl)oxy]phenyl}piperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-ethoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-cyclopropylphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(4-propoxyphenyl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, N-{4-[1-(3-cyano-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)piperidin-4-yl]phenyl}benzenesulfonamide, 4-[4-(3-cyclopropylphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(dimethylamino)phenyl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(propan-2-yl)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(Benzyloxy)phenyl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, N-{4-[1-(3-cyano-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)piperidin-4-yl]phenyl}benzamide, 1-methyl-4-[4-(1-methyl-1H-indol-5-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-fluoro-5-methylphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(2-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-([1,1'-biphenyl]-4-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-chlorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(4-phenoxyphenyl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-(4-methyl-4-phenylpiperidin-1-yl)-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(2-oxopyrrolidin-1-yl)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(2-Fluorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(trifluoromethyl)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-Fluorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[3-(morpholin-4-yl)phenyl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(naphthalen-1-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-4-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[1-methyl-3-(trifluoroacetyl)-1H-indol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1-benzofuran-7-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(isoquinolin-7-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-7-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, N-{3-[1-(3-cyano-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)piperidin-4-yl]phenyl}benzamide, 4-[4-(4-Fluorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methylphenyl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(4-methylphenyl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[3-(difluoromethyl)phenyl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-bromophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-Bromo-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-Bromo-1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-7-phenyl-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3,7-dicarbonitrile, 7-cyclopropyl-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(2,2-dimethyl-2λ 6 -diazathia-1,2-dien-1-yl)-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-7-(oxetan-3-yl)-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(Methylsulfonyl)-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(3,6-dihydro-2H-pyran-4-yl)-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1-benzofuran-4-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-(4-{4-[(propan-2-yl)oxy]phenyl}piperidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-ethylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-2-oxo-4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carboxamide, 4-[4-(5,6-difluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-Bromo-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-Methyl-4-[3-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, stereoisomer mixture, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-7-(oxetan-3-yl)-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, (rac)-1-methyl-2-oxo-4-{4-[4-(propan-2-yl)phenyl]azepan-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{(4S)-4-[4-(propan-2-yl)phenyl]azepan-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{(4R)-4-[4-(propan-2-yl)phenyl]azepan-1-yl}-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-(1,3-benzoxazol-2-yl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-{4-[(propan-2-yl)oxy]phenyl}azepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-(4-methoxyphenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4R)-4-(4-methoxyphenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4S)-4-(4-methoxyphenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-(1,3-benzoxazol-2-yl)azepan-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4R)-4-(1,3-benzoxazol-2-yl)azepan-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4S)-4-(1,3-benzoxazol-2-yl)azepan-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-(4-chlorophenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4R)-4-(4-chlorophenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4S)-4-(4-chlorophenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-7-bromo-1-methyl-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-7-(oxetan-3-yl)-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-7-(morpholin-4-yl)-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-7-bromo-1-methyl-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carboxamide, 7-Bromo-1-methyl-2-oxo-4-[(4S)-4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carboxamide, 4-[4-ethyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-4-[4-ethyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-N,1-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 8-Fluoro-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-8-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-(Methylsulfonyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-6-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-6-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzooxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 6-(Methylsulfonyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzooxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-methyl-4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-methyl-4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-methyl-4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzooxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carboxamide, 4-[4-(5-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(6-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)azepan-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)azepan-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-6-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 6-cyano-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-(3,3-difluorocyclobutyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(Methoxymethyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(methoxymethyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-Fluoro-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-6-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-Fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,7-dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,7-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-ethylpiperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-Chloro-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[(2S,4S)-2-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-Fluoro-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-Fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(1-hydroxycyclopropyl)methoxy]-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-Hydroxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(Cyclopropyloxy)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-8-(oxetan-3-yl)-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(Cyclobutyloxy)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-methoxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,7-dicarbonitrile, 7-cyclopropyl-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(1-cyanocyclopropyl)methoxy]-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(3,3-difluorocyclobutyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-8-[(oxetan-3-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5,6-difluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,7-dimethyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 7-methoxy-1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-propoxy-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro-1,3-benzooxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-methoxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-(oxetan-3-yl)-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-(Cyclopropyloxy)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,8-Dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(Cyclopropyloxy)-1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[5-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[6-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[5-(oxetan-3-yl)-1,3-benzooxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carbonitrile, 7-Hydroxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-bromo-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[5-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-6-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-6-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-Fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-8-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,7-dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,7-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[4-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[6-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 4-[4-(4,5-dimethyl-1,3-thiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3,4-dimethoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-chlorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[(2S,4S)-2-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)-1-piperidinyl]-2-oxo-quinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-acetylphenyl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1-benzothiophen-2-yl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1-benzothiophen-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-methoxynaphthalen-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methyl-1,3-benzoxazol-5-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methyl-1,3-benzothiazol-5-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3,3-dimethyl-2,3-dihydro-1H-indol-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[(2R)-2-methyl-2,3-dihydro-1-benzofuran-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(1,3,3-trimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(2-hydroxy-2,3-dihydro-1H-inden-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(2,2-dimethyl-2H-1,3-benzodioxolan-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(2'-oxo-1',2'-dihydrospiro[cyclobutane-1,3'-indol]-5'-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(4-methylquinolin-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-Fluoro-1-methyl-1H-indol-6-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[1-(3-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[1-(4-chlorophenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methylquinolin-6-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(3-methoxyphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(2-methoxyphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-dimethyl-1H-indazol-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methyl-1,3-benzoxazol-6-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methyl-1,3-benzothiazol-6-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[3-(difluoromethyl)quinolin-7-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, 1-Methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile 1-Methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxa-4-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(2-methoxyethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-{[oxiran-2-yl]methoxy}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-methoxy-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-(4-{5-[(oxolan-2-yl)methoxy]-1,3-benzoxazol-2-yl}piperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[6-(oxetan-3-yl)-1,3-benzooxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-fluoropiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[5-(methoxymethyl)-1,3-benzoxazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[6-(methoxymethyl)-1,3-benzoxazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-cyclopropyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-cyclopropyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[methyl(oxetan-3-yl)amino]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-hydroxyethyl)(methyl)amino]-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[methyl(oxolan-3-yl)amino]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(Cyanomethyl)(methyl)amino]-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 3-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-6-carboxamide, 6-ethoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(2,2-difluoropropoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(2,2-difluoroethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(Cyclopropylmethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-cyclobutyl-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-6-(3,3,3-trifluoroprop-1-en-2-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-6-[1-(trifluoromethyl)cyclopropyl]-1,2-dihydroquinoline-3-carbonitrile, 2-({3-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinolin-7-yl}oxy)acetamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-{[oxa-3-yl]oxy}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, ({3-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinolin-7-yl}oxy)acetic acid, (rac)-4-[4-fluoro-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(oxolan-3-yloxy)-1,2-dihydroquinoline-3-carbonitrile, 7-(Cyclopropylamino)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-methoxy-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-4-[4-fluoro-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-hydroxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-hydroxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[oxolan-3-yloxy]-1,2-dihydroquinoline-3,6-dicarbonitrile, 7-Hydroxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile (rac)-6-ethoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[oxolan-3-yloxy]-1,2-dihydroquinoline-3-carbonitrile, 7-Hydroxy-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[oxolan-3-yloxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-(2,2-difluoroethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[oxolan-3-yloxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-fluoro-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-6-methoxy-1-methyl-2-oxo-7-[oxolan-3-yloxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3,6-dicarbonitrile, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-6-(3,3,3-trifluoroprop-1-en-2-yl)-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-2-oxo-4-(4-{5-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}piperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-{4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-2-oxo-4-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-2-oxo-4-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-2-oxo-4-[4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-4-{4-[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-hydroxy-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-7-{[oxa-3-yl]oxy}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, N,1-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-N,1-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1-benzothiophen-2-yl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1-benzothiophen-2-yl)-4-hydroxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(6-methoxynaphthalen-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[2-methyl-2,3-dihydro-1-benzofuran-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(2-hydroxy-2,3-dihydro-1H-inden-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(2,2-dimethyl-2H-1,3-benzodioxolan-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-2-oxo-4-[4-(2'-oxo-1',2'-dihydrospiro[cyclobutane-1,3'-indol]-5'-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-methyl-4-(4-methylquinolin-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(4-fluoro-1-methyl-1H-indol-6-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[1-(3-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[4-(3-methoxyphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[4-(2-methoxyphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-(2-methoxyethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-{[oxiran-2-yl]methoxy}-2-oxo-1,2-dihydroquinoline-3-carboxamide, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, (-)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, (+)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(5-methoxy-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-2-oxo-4-(4-{5-[(oxolan-2-yl)methoxy]-1,3-benzoxazol-2-yl}piperidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-fluoropiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[5-(methoxymethyl)-1,3-benzoxazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[6-(methoxymethyl)-1,3-benzoxazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[methyl(oxetan-3-yl)amino]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-[(2-hydroxyethyl)(methyl)amino]-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-[(Cyanomethyl)(methyl)amino]-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-(2-amino-2-oxoethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-fluoro-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 6-bromo-7-hydroxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-7-hydroxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, (rac)-6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, (rac)-6-cyano-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-2-oxo-4-(4-{5-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}piperidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-4-{4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-2-oxo-4-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-2-oxo-4-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-2-oxo-4-[4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-4-{4-[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-7-hydroxy-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-7-methoxy-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-hydroxy-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-bromo-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-bromo-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, (rac)-6-cyano-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, (-)-6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, (rac)-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 7-[(2-methoxyethyl)amino]-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(3-hydroxyazetidin-1-yl)-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)amino]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-hydroxyethyl)amino]-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-hydroxyethyl)(methyl)amino]-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-methoxyethyl)amino]-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-(3-hydroxyazetidin-1-yl)-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, (rac)-1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-hydroxyethyl)amino]-1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-hydroxyethyl)amino]-1,6-dimethyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-cyano-7-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, (rac)-6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(oxolan-3-yl)methyl]amino}-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-({[(3R)-oxolan-3-yl]methyl}amino)-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-({[(3S)-oxolan-3-yl]methyl}amino)-1,2-dihydroquinoline-3-carboxamide, 6-chloro-7-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-chloro-7-hydroxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, (rac)-6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)methoxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)methoxy]-1,2-dihydroquinoline-3-carboxamide, 6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]methoxy}-1,2-dihydroquinoline-3-carboxamide, 6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]methoxy}-1,2-dihydroquinoline-3-carboxamide, (rac)-6-bromo-1-methyl-2-oxo-7-[(oxolan-3-yl)oxy]-4-{4-[2-(pyridin-3-yl)-2H-1,2,3-triazol-4-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-bromo-1-methyl-4-{4-[1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1,6-dimethyl-4-{4-[1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, and (rac)-1,6-dimethyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-4-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile.

Images